CRMR RESO DE STRASBOURG

Liste des publications sur les maladies auto-immunes du CRMR RESO de Strasbourg

Le CRMR RESO de Strasbourg assure une très importante activité de recherche scientifique fondamentale, translationnelle et clinique donnant lieu à de très nombreuses publications nationales et internationales de premier plan dans le domaine des maladies auto-immunes et des maladies immunologiques rares. Ces publications ont un très fort retentissement pour la prise en charge diagnostique et thérapeutique des patients.

Liste des publications du CRMR RESO des 5 dernières années

  1. Koyner JL, Arndt C, Baldira Martinez de Irujo J, Coelho S, Garcia-Montesinos de la Peña M, di Girolamo L, et al. Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meeting. Ren Fail. déc 2024;46(1):2345747.
  2. Nguyen Y, Mariette X, Gottenberg JE, Iudici M, Morel J, Vittecoq O, et al. Can efficacy and safety data from clinical trials of rituximab in RA be extrapolated? Insights from 1984 patients from the AIR-PR Registry. Rheumatology (Oxford). 1 juill 2024;63(7):1893‑901.
  3. Mosca M, Bruce IN, Andersen J, Ugarte-Gil MF, Arnaud L. Challenges and opportunities in access to care for systemic lupus erythematosus patients across Europe and worldwide. Rheumatology (Oxford). 1 juill 2024;63(7):1772‑8.
  4. Teboul A, Arnaud L, Chasset F. Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know. J Dermatol. juill 2024;51(7):895‑903.
  5. Rossignol J, Canioni D, Aouba A, Bulai-Livideanu C, Barete S, Lancesseur C, et al. Histological characterization of liver involvement in systemic mastocytosis. Liver Int. juill 2024;44(7):1680‑8.
  6. Emad Y, Ragab Y, Farber HW, Erkan D, Ibrahim O, Kindermann M, et al. Pulmonary embolism versus pulmonary vasculitis in Hughes-Stovin syndrome: Characteristic computed tomography pulmonary angiographic findings and diagnostic and therapeutic implications. HSS International Study Group. Thromb Res. juill 2024;239:109040.
  7. Boudjeniba C, Soret P, Trutschel D, Hamon A, Baloche V, Chassagnol B, et al. Consensus gene modules strategy identifies candidate blood-based biomarkers for primary Sjögren’s disease. Clin Immunol. juill 2024;264:110241.
  8. Cauchois R, Lagarde M, Muller R, Faccini J, Leroyer A, Arnaud L, et al. VE-Cadherin is involved in endothelial cell detachment during Thrombotic Thrombocytopenic Purpura. J Thromb Haemost. 29 juin 2024;S1538-7836(24)00371-4.
  9. Ali EAM, Smaida R, Meyer M, Ou W, Li Z, Han Z, et al. iPSCs chondrogenic differentiation for personalized regenerative medicine: a literature review. Stem Cell Res Ther. 26 juin 2024;15(1):185.
  10. Abad C, Pinal-Fernandez I, Guillou C, Bourdenet G, Drouot L, Cosette P, et al. IFNγ causes mitochondrial dysfunction and oxidative stress in myositis. Nat Commun. 26 juin 2024;15(1):5403.
  11. Driouich JS, Cochin M, Lingas G, Luciani L, Baronti C, Bernadin O, et al. Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages. Biomed Pharmacother. 18 juin 2024;177:116988.
  12. Pan W, Tsokos MG, Scherlinger M, Li W, Tsokos GC. The PP2A regulatory subunit PPP2R2A controls NAD(+) biosynthesis to regulate T cell subset differentiation in systemic autoimmunity. Cell Rep. 17 juin 2024;43(7):114379.
  13. Alle G, Guettrot-Imbert G, Larosa M, Murarasu A, Lazaro E, Morel N, et al. Hydroxychloroquine levels in pregnancy and materno-fetal outcomes in Systemic Lupus Erythematosus patients. Rheumatology (Oxford). 5 juin 2024;keae302.
  14. Moussa MK, Lefèvre N, Valentin E, Khalaf Z, Meyer A, Grimaud O, et al. Association of Patient-Surgeon and Patient-Physical Therapist Relationships With Return to Sports After ACL Reconstruction: The Untested Dimension in Outcome Assessments. Orthop J Sports Med. juin 2024;12(6):23259671241254749.
  15. Moraly J, Rossignol J, Rouzaud C, Gabas T, Bouktit H, Lhermitte L, et al. Efficacy and safety of mammalian target of rapamycin inhibitors in systemic mastocytosis: A nationwide French pilot study. Am J Hematol. juin 2024;99(6):1095‑102.
  16. Mertz P, Costedoat-Chalumeau N, Ferrada MA, Moulis G, Mekinian A, Grayson PC, et al. Relapsing polychondritis: clinical updates and new differential diagnoses. Nat Rev Rheumatol. juin 2024;20(6):347‑60.
  17. Masseran C, Perray L, Murat de Montai Q, Mathian A, Teboul A, Francès C, et al. Comparison of patients with isolated cutaneous lupus erythematosus versus systemic lupus erythematosus with cutaneous lupus erythematosus as the sole clinical feature: A monocentric study of 149 patients. J Am Acad Dermatol. juin 2024;90(6):1210‑7.
  18. Giorgiutti S, Rottura J, Korganow AS, Gies V. CXCR4: from B-cell development to B cell-mediated diseases. Life Sci Alliance. juin 2024;7(6).
  19. Bouché PA, Lefevre N, Bohu Y, Gerometta A, Meyer A, Grimaud O, et al. Comparison of the retear rate 2years after ACL reconstruction with the Tape Locking Screw short graft system and the STG technique: A case control study with propensity score matching. Orthop Traumatol Surg Res. juin 2024;110(4):103848.
  20. Hoi A, Igel T, Mok CC, Arnaud L. Systemic lupus erythematosus. Lancet. 25 mai 2024;403(10441):2326‑38.
  21. Wendling D, Breban M, Costantino F, Lequerré T, Felten R, Ruyssen-Witrand A, et al. Unmet needs in axial spondyloarthritis. Proceedings of the French spondyloarthritis taskforce workshop. Joint Bone Spine. 23 mai 2024;91(6):105741.
  22. Burmester GR, Gottenberg JE, Caporali R, Winthrop KL, Tanaka Y, Ekoka Omoruyi EV, et al. Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years. Ann Rheum Dis. 23 mai 2024;ard-2024-225759.
  23. Hadjadj J, Nguyen Y, Mouloudj D, Bourguiba R, Heiblig M, Aloui H, et al. Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX. Ann Rheum Dis. 22 mai 2024;ard-2024-225640.
  24. Parodis I, Girard-Guyonvarc’h C, Arnaud L, Distler O, Domján A, Van den Ende CHM, et al. EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. Ann Rheum Dis. 15 mai 2024;83(6):720‑9.
  25. Sztejkowski C, Sibilia J, Danion F, Mertz P, Elodie F, Kassegne L, et al. Combining ts- and a bDMARD in refractory rheumatoid arthritis: an unusual adverse event. Rheumatology (Oxford). 3 mai 2024;63(6):e185‑7.
  26. Thibault T, Rajillah A, Bourredjem A, Corneloup M, Maurier F, Wahl D, et al. Health-related quality of life, remission and low lupus disease activity state in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2 mai 2024;63(5):1447‑55.
  27. Tsoi A, Gomez A, Boström C, Pezzella D, Chow JW, Girard-Guyonvarc’h C, et al. Efficacy of lifestyle interventions in the management of systemic lupus erythematosus: a systematic review of the literature. Rheumatol Int. mai 2024;44(5):765‑78.
  28. Sibilia J, Berna F, Bloch JG, Scherlinger M. Mind-body practices in chronic inflammatory arthritis. Joint Bone Spine. mai 2024;91(3):105645.
  29. Sibilia J. [Three years of reform of the first year of health studies and now?]. Rev Prat. mai 2024;74(5):467.
  30. Huang F, Khellaf LR, Lefèvre G, Berti A, d’Humières T, Sionis A, et al. Clinical picture, outcomes, and predictors of relapse in eosinophilia-associated coronary vasospasm: Data from a European multicentric study. J Allergy Clin Immunol Pract. mai 2024;12(5):1377-1381.e2.
  31. Giannini M, Debrut L, Nespola B, Velten M, Geny B, Sibilia J, et al. Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups. Nat Rev Rheumatol. mai 2024;20(5):311‑2.
  32. Riou M, Coste F, Meyer A, Enache I, Talha S, Charloux A, et al. Mechanisms of Pulmonary Vasculopathy in Acute and Long-Term COVID-19: A Review. Int J Mol Sci. 30 avr 2024;25(9).
  33. Hassold N, Dusser P, Laurent A, Lemelle I, Pillet P, Comarmond C, et al. Clinical spectrum and outcome of Takayasu’s arteritis in children. Joint Bone Spine. 15 avr 2024;91(5):105735.
  34. Kaseb A, Giannini M, Dramé B, Willaume T, Meyer A, Imperiale A. Taming the tiger: Insights into sarcoid myositis through 18F-FDG PET/MRI imaging. QJM. 12 avr 2024;hcae075.
  35. Ruyssen-Witrand A, Caillet-Portillo D, Najm A, Fogel O, Baillet A, Claudepierre P, et al. Standardized reporting for systematic global evaluation of axial spondyloarthritis: An evidence-based and consensus-driven initiative. Joint Bone Spine. 9 avr 2024;91(5):105733.
  36. Wendling D, Al Tabaa O, Chevet B, Fakih O, Ghossan R, Hecquet S, et al. Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumatica. Joint Bone Spine. 5 avr 2024;91(4):105730.
  37. Paradis S, Charles AL, Giannini M, Meyer A, Lejay A, Talha S, et al. Targeting Mitochondrial Dynamics during Lower-Limb Ischemia Reperfusion in Young and Old Mice: Effect of Mitochondrial Fission Inhibitor-1 (mDivi-1). Int J Mol Sci. 4 avr 2024;25(7).
  38. Blaess J, Geneton S, Goepfert T, Appenzeller S, Bordier G, Davergne T, et al. Recommendations for physical activity and exercise in persons living with Systemic Lupus Erythematosus (SLE): consensus by an international task force. RMD Open. 4 avr 2024;10(2).
  39. Culerrier J, Nguyen Y, Karadag O, Yasar Bilge S, Yildrim TD, Ögüt TS, et al. Characteristics and outcome of ANCA-associated vasculitides induced by anti-thyroid drugs: a multicentre retrospective case-control study. Rheumatology (Oxford). 2 avr 2024;63(4):999‑1006.
  40. Nguyen Y, Nocturne G, Henry J, Ng WF, Belkhir R, Desmoulins F, et al. Identification of distinct subgroups of Sjögren’s disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts. Lancet Rheumatol. avr 2024;6(4):e216‑25.
  41. Naye F, Toupin-April K, de Wit M, LeBlanc A, Dubois O, Boonen A, et al. OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments. Semin Arthritis Rheum. avr 2024;65:152344.
  42. Morgado D, Fanesi A, Martin T, Tebbani S, Bernard O, Lopes F. Non-destructive monitoring of microalgae biofilms. Bioresour Technol. avr 2024;398:130520.
  43. Lefèvre N, Freiha K, Moussa MK, Valentin E, Bohu Y, Meyer A, et al. Risk Factors for Rerupture After Proximal Hamstring Avulsion Injury Including the Optimal Timing for Surgery. Am J Sports Med. avr 2024;52(5):1173‑82.
  44. Kedra J, Dieudé P, Giboin C, Marotte H, Salliot C, Schaeverbeke T, et al. Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission. Arthritis Rheumatol. avr 2024;76(4):541‑52.
  45. Décary S, de Wit M, Naye F, Barton JL, Fraenkel L, Li LC, et al. Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials. Semin Arthritis Rheum. avr 2024;65:152381.
  46. Giannini M, Charles AL, Evrard C, Blaess J, Bouchard-Marmen M, Debrut L, et al. Title: Sarcopenia assessed by DXA and hand-grip dynamometer: a potential marker of damage, disability and myokines imbalance in inflammatory myopathies. Rheumatology (Oxford). 27 mars 2024;keae207.
  47. Felten R, Fabacher T, Sedmak N, Sibilia J, Sordet C, Chatelus E, et al. Repurposing the Fibrosis-4 Score in Rheumatoid Arthritis: Data from the ESPOIR Cohort. J Clin Med. 26 mars 2024;13(7).
  48. D’Agostino J, Souki A, Lohse A, Carvajal Alegria G, Dernis E, Richez C, et al. Concordance and agreement between different activity scores in polymyalgia rheumatica. RMD Open. 15 mars 2024;10(1).
  49. Winthrop KL, Mease P, Kerschbaumer A, Voll RE, Breedveld FC, Smolen JS, et al. Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023. Ann Rheum Dis. 12 mars 2024;83(4):409‑16.
  50. Astouati Q, Machet T, Houssais C, Noury JB, Allenbach Y, Gallay L, et al. Inclusion-body myositis associated with Sjögren’s disease: clinical characteristics and comparison with other Sjögren-associated myositis. Rheumatology (Oxford). 1 mars 2024;keae129.
  51. Solitano V, Facheris P, Petersen M, D’Amico F, Ortoncelli M, Aletaha D, et al. Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study. Autoimmun Rev. mars 2024;23(3):103504.
  52. Moussa MK, Lefèvre N, Valentin E, Coughlan A, Zgolli A, Gerometta A, et al. Impact of Lateral Extra-Articular Procedure Augmentation on Rerupture Risk and Tegner Activity Scale Outcomes in Adolescent Anterior Cruciate Ligament: A Matched Comparative Study With a Minimum 2-Year Follow-up. Am J Sports Med. mars 2024;52(4):892‑901.
  53. Morgado D, Fanesi A, Martin T, Tebbani S, Bernard O, Lopes F. Exploring the dynamics of astaxanthin production in Haematococcus pluvialis biofilms using a rotating biofilm-based system. Biotechnol Bioeng. mars 2024;121(3):991‑1004.
  54. Mathian A, Felten R, Alarcon-Riquelme ME, Psarras A, Mertz P, Chasset F, et al. Type 1 interferons: A target for immune-mediated inflammatory diseases (IMIDs). Joint Bone Spine. mars 2024;91(2):105627.
  55. Lefèvre N, Moussa MK, Valentin E, Meyer A, Bohu Y, Gerometta A, et al. Predictors of Early Return to Sport After Surgical Repair of Proximal Hamstring Complex Injuries in Professional Athletes: A Prospective Study. Am J Sports Med. mars 2024;52(4):1005‑13.
  56. Lefevre N, Kassab Hassan S, Valentin E, Bohu Y, Gerometta A, Meyer A, et al. Validation of the Parisian Hamstring Avulsion Score (PHAS) in the Evaluation and Follow-up of Patients Operated for Proximal Hamstring Avulsion. Am J Sports Med. mars 2024;52(4):1014‑21.
  57. Lauper K, Mongin D, Bergstra SA, Choquette D, Codreanu C, Gottenberg JE, et al. Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies. Joint Bone Spine. mars 2024;91(2):105671.
  58. Meudec L, Debray MP, Beurnier A, Marques C, Juge PA, Dhote R, et al. Characterisation of airway disease associated with Sjögren disease. RMD Open. 29 févr 2024;10(1).
  59. Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease – A Case Series with Follow-up. N Engl J Med. 22 févr 2024;390(8):687‑700.
  60. Moulin D, Millard M, Taïeb M, Michaudel C, Aucouturier A, Lefèvre A, et al. Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis. Ann Rheum Dis. 15 févr 2024;83(3):312‑23.
  61. de Valence B, Delaune M, Nguyen Y, Jachiet V, Heiblig M, Jean A, et al. Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry. Ann Rheum Dis. 15 févr 2024;83(3):372‑81.
  62. Arnaud L, Parodis I, Devilliers H, Chasset F. Clinical trial outcomes for SLE: what we have and what we need. Lupus Sci Med. 15 févr 2024;11(1).
  63. Guffroy A, Jacquel L, Guffroy B, Martin T. CAR-T cells for treating systemic lupus erythematosus: A promising emerging therapy. Joint Bone Spine. 7 févr 2024;91(5):105702.
  64. Marmen MB, Ohana M, Von Hunolstein JJ, Lannes B, Meyer A. Skeletal and Cardiac Muscle Hydroxychloroquine Toxicity. J Rheumatol. 1 févr 2024;51(2):207.
  65. Lioté F, Constantin A, Dahan É, Quiniou JB, Frazier A, Sibilia J. A prospective survey on therapeutic inertia in psoriatic arthritis (OPTI’PsA). Rheumatology (Oxford). 1 févr 2024;63(2):516‑24.
  66. Giannini M, Meyer A. Comment on: Inaugural dropped head syndrome and camptocormia in inflammatory myopathies: a retrospective study. Rheumatology (Oxford). 1 févr 2024;63(2):e60.
  67. Loganathan A, Zanframundo G, Yoshida A, Faghihi-Kashani S, Bauer Ventura I, Dourado E, et al. Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank. Clin Exp Rheumatol. févr 2024;42(2):277‑87.
  68. Eschbach J, Wagner A, Beahr C, Bekel A, Korganow AS, Quartier A, et al. Drug upgrade: A complete methodology from old drug to new chemical entities using Nematic Protein Organization Technique. Drug Dev Res. févr 2024;85(1):e22151.
  69. Chehem Daoud Chehem F, de Mornac D, Feuillet F, Liozon E, Samson M, Bonnotte B, et al. Giant cell arteritis associated with scalp, tongue or lip necrosis: A French multicenter case control study. Semin Arthritis Rheum. févr 2024;64:152348.
  70. Caillet Portillo D, Puéchal X, Masson M, Kostine M, Michaut A, Ramon A, et al. Diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease: Data from the French Tw-IRD registry. J Infect. févr 2024;88(2):132‑8.
  71. Boelen C, Sibilia J, Maherzi A, De Munck P. [Using the social responsibility strategy to overhaul the healthcare system]. Rev Prat. févr 2024;74(2):129‑32.
  72. Abid H, Rougereau G, Bohu Y, Meyer A, Gerometta A, Grimaud O, et al. French Version of the Short Anterior Cruciate Ligament-Return to Sport After Injury Scale: Development and Validation. Orthop J Sports Med. févr 2024;12(2):23259671231220959.
  73. Bausson J, Keller N, Von Hunolstein JJ, Sacrez M, Michel B, Gourieux B, et al. Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease. RMD Open. 31 janv 2024;10(1).
  74. Scherlinger M, Li H, Pan W, Li W, Karino K, Vichos T, et al. CaMK4 controls follicular helper T cell expansion and function during normal and autoimmune T-dependent B cell responses. Nat Commun. 29 janv 2024;15(1):840.
  75. Lemogne C, Gouraud C, Ouazana Vedrines C, Pritschkat C, Rotenberg L, Horn M, et al. National committee statement as a missed opportunity to acknowledge the relevance of a biopsychosocial approach in understanding long COVID. J Psychosom Res. 22 janv 2024;111596.
  76. De Moreuil C, Diot E, Agard C, Belhomme N, Lescoat A, Queyrel V, et al. History of pre-eclampsia does not appear to be a risk factor for vascular phenotype in women with systemic sclerosis. RMD Open. 4 janv 2024;10(1).
  77. Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2 janv 2024;83(1):15‑29.
  78. Berry JS, Tarn J, Casement J, Duret PM, Scott L, Wood K, et al. Examining the biological pathways underlying clinical heterogeneity in Sjogren’s syndrome: proteomic and network analysis. Ann Rheum Dis. 2 janv 2024;83(1):88‑95.
  79. Kaseb A, Bessac D, Frantzen L, Herber M, Poindron V, Imperiale A. 18 F-FDG PET/MRI for Diagnosis and Treatment Efficacy Evaluation of Spinal Sarcoidosis. Clin Nucl Med. 1 janv 2024;49(1):e28‑30.
  80. Robert M, Scherlinger M. Platelets are a major player and represent a therapeutic opportunity in systemic lupus erythematosus. Joint Bone Spine. janv 2024;91(1):105622.
  81. Reuschlé Q, Van Heddegem L, Bosteels V, Moncan M, Depauw S, Wadier N, et al. Loss of function of XBP1 splicing activity of IRE1α favors B cell tolerance breakdown. J Autoimmun. janv 2024;142:103152.
  82. Polivka L, Madrange M, Bulai-Livideanu C, Barete S, Ballul T, Neuraz A, et al. Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes. J Allergy Clin Immunol. janv 2024;153(1):349-353.e4.
  83. Pickering ME, Javier RM, Malochet S, Pickering G, Desmeules J. Osteoporosis treatment and pain relief: A scoping review. Eur J Pain. janv 2024;28(1):3‑20.
  84. Mathian A, Arnaud L, Ruiz-Irastorza G. Is it safe to withdraw low-dose glucocorticoids in SLE patients in remission? Autoimmun Rev. janv 2024;23(1):103446.
  85. Karam KM, Moussa MK, Valentin E, Meyer A, Bohu Y, Gerometta A, et al. Sustainability studies in orthopaedic surgery: The carbon footprint of anterior cruciate ligament reconstruction depends on graft choice. Knee Surg Sports Traumatol Arthrosc. janv 2024;32(1):124‑34.
  86. Ghergus D, Martin M, Knapp AM, Delmotte F, Joublin-Delavat A, Jung S, et al. Normal B cells express ZAP70 in chronic lymphocytic leukemia: A link between autoimmunity and lymphoproliferation? Am J Hematol. janv 2024;99(1):48‑56.
  87. Fares A, Hardy A, Bohu Y, Meyer A, Karam K, Lefevre N. The impact of bone graft type used to fill bone defects in patients undergoing ACL reconstruction with bone-patellar tendon-bone (BPTB) autograft on kneeling, anterior knee pain and knee functional outcomes. Eur J Orthop Surg Traumatol. janv 2024;34(1):181‑90.
  88. Deibel E, Carreira PE, Vonk M, Del Papa N, Bečvář R, Guillén-Del-Castillo A, et al. Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time? Arthritis Care Res (Hoboken). janv 2024;76(1):88‑97.
  89. Pasquer R, Dieudonné Y, Decours P, Hinschberger O, Nicolae A, Martinot M. HHV8-Positive Multicentric Castleman’s Disease and Thrombotic Thrombocytopenic Purpura among HIV-Positive Patients. Eur J Case Rep Intern Med. 2024;11(3):004361.
  90. Arnaud L, Furie R, Morand EF, Aringer M, Peschken C, Desta B, et al. Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature. Lupus Sci Med. 20 déc 2023;10(2).
  91. Kawka L, Sarmiento-Monroy JC, Mertz P, Pijnenburg L, Rinagel M, Ugarte-Gil MF, et al. Assessment and personalised advice for fatigue in systemic lupus erythematosus using an innovative digital tool: the Lupus Expert system for the Assessment of Fatigue (LEAF) study. RMD Open. 6 déc 2023;9(4).
  92. Saraux A, Le Henaff C, Dernis E, Carvajal-Alegria G, Tison A, Quere B, et al. Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial. Lancet Rheumatol. déc 2023;5(12):e728‑35.
  93. Haidar I, Hardy A, Bohu Y, Meyer A, Lefevre N. Clinical outcomes of arthroscopic partial resection of mucoid degeneration of anterior cruciate ligament. Int Orthop. déc 2023;47(12):2961‑5.
  94. Felten R, Toussirot E. Current Pharmacological Therapies for the Management of Spondyloarthritis: Special Considerations in Older Patients. Drugs Aging. déc 2023;40(12):1101‑12.
  95. Askanase A, Khalili L, Tang W, Mertz P, Scherlinger M, Sebbag E, et al. New and future therapies: Changes in the therapeutic armamentarium for SLE. Best Pract Res Clin Rheumatol. déc 2023;37(4):101865.
  96. Abou Al Ezz M, Gerometta A, Valentin E, Meyer A, Grimaud O, Lefevre N, et al. Comparison of Revision ACL Reconstruction Using Iliotibial Band Augmented With Allograft Versus Bone-Patellar Tendon-Bone Autograft With Lateral Extra-articular Tenodesis. Orthop J Sports Med. déc 2023;11(12):23259671231214803.
  97. Sajan M, Moussa MK, Lefèvre N, Payan C, Valentin E, Meyer A, et al. Customized-individually-made origin® implants in total knee arthroplasty allow a reliable solution for accurate reproduction of planned implant positioning. J Exp Orthop. 28 nov 2023;10(1):123.
  98. Guervilly C, Bousquet G, Arnaud L, Gragueb-Chatti I, Daviet F, Adda M, et al. Microvesicles Are Associated with Early Veno Venous ECMO Circuit Change during Severe ARDS: A Prospective Observational Pilot Study. J Clin Med. 24 nov 2023;12(23).
  99. Odler B, Tieu J, Artinger K, Chen-Xu M, Arnaud L, Kitching RA, et al. The plethora of immunomodulatory drugs: opportunities for immune-mediated kidney diseases. Nephrol Dial Transplant. 8 nov 2023;38(Supplement_2):ii19‑28.
  100. Guédon AF, Carrat F, Mouthon L, Launay D, Chaigne B, Pugnet G, et al. Heart and systemic sclerosis-findings from a national cohort study. Rheumatology (Oxford). 7 nov 2023;kead599.
  101. Felten R, Ye T, Schleiss C, Schwikowski B, Sibilia J, Monneaux F, et al. Identification of new candidate drugs for primary Sjögren’s syndrome using a drug repurposing transcriptomic approach. Rheumatology (Oxford). 2 nov 2023;62(11):3715‑23.
  102. Scherlinger M, Schaeverbeke T. Correspondence on « Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting ». Ann Rheum Dis. nov 2023;82(11):e221.
  103. Le Voyer T, Parent AV, Liu X, Cederholm A, Gervais A, Rosain J, et al. Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency. Nature. nov 2023;623(7988):803‑13.
  104. Le Roux E, Bourmaud A, Jacquin P, Mahlaoui N, Guffroy A, Belot A, et al. Clinics dedicated to transition preparation for adolescents and young adults with chronic conditions: Factors influencing their use. Arch Pediatr. nov 2023;30(8):617‑9.
  105. Felten R, Widawski L, Spielmann L, Gaillez C, Bao W, Gottenberg JE, et al. Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2-5 and MAXIMISE studies. RMD Open. nov 2023;9(4).
  106. Battesti G, Felten R, Piga M, Sarmiento-Monroy JC, Ziade N, El Kibbi L, et al. Prevalence, characteristics, and knowledge related to photosensitivity in patients with lupus erythematosus: the international PHOTOLUP study. Rheumatology (Oxford). 10 oct 2023;kead548.
  107. Jung S, Gavriiloglou M, Séverac F, Haumesser L, Sayeh A, Chatelus E, et al. Influence of systemic sclerosis on periodontal health: A case-control study. J Clin Periodontol. oct 2023;50(10):1348‑59.
  108. Duret PM, Schleiss C, Kawka L, Meyer N, Ye T, Saraux A, et al. Association Between Bruton’s Tyrosine Kinase Gene Overexpression and Risk of Lymphoma in Primary Sjögren’s Syndrome. Arthritis Rheumatol. oct 2023;75(10):1798‑811.
  109. Debrut L, Giannini M, Klein D, Spielmann L, Mertz P, Martin T, et al. Refining Incidence and Characteristics of Inflammatory Myopathies: A Quadruple-Source Capture-Recapture Survey Using the 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria. Arthritis Rheumatol. oct 2023;75(10):1850‑5.
  110. Savel C, Chausset A, Berland P, Guiguet-Auclair C, Cabane L, Fautrel B, et al. Survey of adolescents’ needs and parents’ views on sexual health in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 5 sept 2023;21(1):95.
  111. Thibault T, Bourredjem A, Maurier F, Wahl D, Muller G, Aumaitre O, et al. The mediating effect of fatigue in impaired quality of life in systemic lupus erythematosus: mediation analysis of the French EQUAL cohort. Rheumatology (Oxford). 1 sept 2023;62(9):3051‑8.
  112. Schreiber K, Giles I, Costedoat-Chalumeau N, Nelson-Piercy C, Dolhain RJ, Mosca M, et al. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases. Lancet Rheumatol. sept 2023;5(9):e501‑6.
  113. Pijnenburg L, Giannini M, Bouchard-Marmen M, Arnaud L, Barsotti S, Bellando-Randone S, et al. In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case-control study. RMD Open. sept 2023;9(3).
  114. Mertz P, Wollenschlaeger C, Chasset F, Dima A, Arnaud L. Rheumatoid vasculitis in 2023: Changes and challenges since the biologics era. Autoimmun Rev. sept 2023;22(9):103391.
  115. Kisten Y, Arnaud L, Levitsky A, Györi N, Larsson P, Hensvold A, et al. Distinct Fluorescence Optical Imaging Patient Clusters Emerge for Seropositive and Seronegative Rheumatoid Arthritis. ACR Open Rheumatol. sept 2023;5(9):474‑80.
  116. Connelly K, Eades LE, Koelmeyer R, Ayton D, Golder V, Kandane-Rathnayake R, et al. Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce. Nat Rev Rheumatol. sept 2023;19(9):592‑602.
  117. Berthelot JM, Lioté F, Sibilia J. Methotrexate also improves rheumatoid arthritis through correction of microbiota dysbiosis. Joint Bone Spine. sept 2023;90(5):105602.
  118. Grimes M, Pauwels K, Schülli TU, Martin T, Fajardo P, Douissard PA, et al. Bragg coherent diffraction imaging with the CITIUS charge-integrating detector. J Appl Crystallogr. 1 août 2023;56(Pt 4):1032‑7.
  119. Bader-Meunier B, Breton S, Duffy D, Gitiaux C, Quartier P, Lemelle I, et al. Osteonecrosis in patients with juvenile dermatomyositis: is it associated with anti-MDA5 autoantibody? Rheumatology (Oxford). 1 août 2023;62(8):e242‑5.
  120. Smits B, Goldacker S, Seneviratne S, Malphettes M, Longhurst H, Mohamed OE, et al. The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease. J Allergy Clin Immunol. août 2023;152(2):528‑37.
  121. Scherlinger M, Richez C, Tsokos GC, Boilard E, Blanco P. The role of platelets in immune-mediated inflammatory diseases. Nat Rev Immunol. août 2023;23(8):495‑510.
  122. Galmiche S, Thoreau B, Bretagne S, Alanio A, Paugam A, Letscher-Bru V, et al. Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network. RMD Open. août 2023;9(3).
  123. Devauchelle-Pensec V, Mariette X, Benyoussef AA, Boisrame S, Cochener B, Cornec D, et al. French national diagnostic and care protocol for Sjögren’s disease. Rev Med Interne. août 2023;44(8):423‑57.
  124. Moussa MK, Lefevre N, Valentin E, Meyer A, Grimaud O, Bohu Y, et al. Dynamic intermittent compression cryotherapy with intravenous nefopam results in faster pain recovery than static compression cryotherapy with oral nefopam: post-anterior cruciate ligament reconstruction. J Exp Orthop. 24 juill 2023;10(1):72.
  125. Robledano A, Picard G, Dumont M, Flin F, Arnaud L, Libois Q. Unraveling the optical shape of snow. Nat Commun. 7 juill 2023;14(1):3955.
  126. Campochiaro C, Hoffmann-Vold AM, Avouac J, Henes J, de Vries-Bouwstra J, Smith V, et al. Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: a EUSTAR database analysis. Rheumatology (Oxford). 5 juill 2023;62(7):2483‑91.
  127. Abbiati M, Severac F, Bajwa N, Sibilia J, Pelaccia T. Validity Evidence of A Screening Tool for Early Detection of Clinical Crisis-Related Anxiety Amongst Medical Students. Teach Learn Med. 2 juill 2023;1‑10.
  128. Jaume L, Fayard D, Breillat P, Francès C, Dutheil A, Barbaud A, et al. Characteristics of cutaneous lupus erythematosus in Black patients, association with systemic lupus and response to treatment: A retrospective cohort study of 141 patients. J Eur Acad Dermatol Venereol. juill 2023;37(7):e868‑71.
  129. Felten R, Mertz P, Sebbag E, Scherlinger M, Arnaud L. Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases. Drug Discov Today. juill 2023;28(7):103612.
  130. Dieudonné Y, Silvestrini MA, Dossier A, Meignin V, Jouenne F, Mahévas T, et al. Paraneoplastic pemphigus uncovers distinct clinical and biological phenotypes of western unicentric Castleman disease. Br J Haematol. juill 2023;202(2):267‑78.
  131. Denis A, Sztejkowski C, Arnaud L, Becker G, Felten R. The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials. RMD Open. juill 2023;9(3).
  132. Chaigne B, Bense A, Agard C, Allanore Y, Pugnet G, Hachulla E, et al. Mouth opening in systemic sclerosis: A longitudinal analysis from the French National Cohort Study. J Intern Med. 27 juin 2023;
  133. Delage L, Carbone F, Riller Q, Zachayus JL, Kerbellec E, Buzy A, et al. NBEAL2 deficiency in humans leads to low CTLA-4 expression in activated conventional T cells. Nat Commun. 22 juin 2023;14(1):3728.
  134. Dominique A, Hetland ML, Finckh A, Gottenberg JE, Iannone F, Caporali R, et al. Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries. Arthritis Res Ther. 12 juin 2023;25(1):101.
  135. Fermon C, Lessard LER, Fenouil T, Meyer A, Faruch-Bilfeld M, Robert M, et al. Revisiting idiopathic eosinophilic myositis: towards a clinical-pathological continuum from the muscle to the fascia and skin. Rheumatology (Oxford). 1 juin 2023;62(6):2220‑9.
  136. Scherlinger M, Richez C, Tsokos GC, Boilard E, Blanco P. Author Correction: The role of platelets in immune-mediated inflammatory diseases. Nat Rev Immunol. juin 2023;23(6):409.
  137. Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. juin 2023;82(6):742‑53.
  138. Felten R, Gottenberg JE. Response to: « Correspondence on “Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial” » by de Wolff et al. Ann Rheum Dis. juin 2023;82(6):e149.
  139. de Frémont GM, Costedoat-Chalumeau N, Lazaro E, Belkhir R, Guettrot-Imbert G, Morel N, et al. Pregnancy outcomes in women with primary Sjögren’s syndrome: an analysis of data from the multicentre, prospective, GR2 study. Lancet Rheumatol. juin 2023;5(6):e330‑40.
  140. Fabacher T, Sauleau EA, Leclerc Du Sablon N, Bergier H, Gottenberg JE, Coulet A, et al. Evaluating the Portability of Rheumatoid Arthritis Phenotyping Algorithms: A Case Study on French EHRs. Stud Health Technol Inform. 18 mai 2023;302:768‑72.
  141. Scherlinger M, Tsokos GC. Neurotransmitters arrive to control systemic autoimmunity. Cell Metab. 2 mai 2023;35(5):728‑9.
  142. Winthrop KL, Isaacs JD, Mease PJ, Boumpas DT, Baraliakos X, Gottenberg JE, et al. Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022. Ann Rheum Dis. mai 2023;82(5):594‑8.
  143. Touret F, Martin-Blondel G, de Lamballerie X, Dupont A, Izopet J, Mentré F, et al. Low to undetectable Omicron BQ.1.1 neutralization by patient’s sera a month after initiation of AZD7442 600 mg. J Infect. mai 2023;86(5):e126‑9.
  144. Mertz P, Arnaud L. [Restatement. Relapsing polychondritis]. Rev Prat. mai 2023;73(5):549‑56.
  145. Kawka L, Felten R, Schleiss C, Fauny JD, Le Van Quyen P, Dumortier H, et al. Alteration of innate lymphoid cell homeostasis mainly concerns salivary glands in primary Sjögren’s syndrome. RMD Open. mai 2023;9(2).
  146. Johnson SR, Gladman DD, Brunner HI, Isenberg D, Clarke AE, Barber MRW, et al. Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). mai 2023;75(5):998‑1006.
  147. Arnaud L, Devilliers H. Correspondence on « Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry ». Ann Rheum Dis. mai 2023;82(5):e113.
  148. Groh M, Rohmer J, Etienne N, Abou Chahla W, Baudet A, Chan Hew Wai A, et al. French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes. Orphanet J Rare Dis. 30 avr 2023;18(1):100.
  149. Landon-Cardinal O, Guillaume-Jugnot P, Toquet S, Sbeih N, Rigolet A, Champtiaux N, et al. JAK inhibitors for the treatment of adult dermatomyositis: A pilot study. J Am Acad Dermatol. avr 2023;88(4):924‑6.
  150. Hmamouchi I, Abi Najm A, El Kibbi L, Metawee M, Halabi H, Abdulateef N, et al. How to optimize recruitment strategies of patients with rheumatic and musculoskeletal diseases for online surveys: experience from an international study. Rheumatol Int. avr 2023;43(4):705‑12.
  151. Talarico R, Ramirez GA, Barreira SC, Cardamone C, Triggianese P, Aguilera S, et al. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products. Clin Exp Rheumatol. mars 2023;41(3):543‑53.
  152. Scherlinger M, Sibilia J, Tsokos GC, Gottenberg JE. Chronic stimulation with SARS-CoV-2 spike protein does not trigger autoimmunity. Clin Immunol. mars 2023;248:109264.
  153. Mertz P, Sparks J, Kobrin D, Ogbonnaya SA, Sevim E, Michet C, et al. Relapsing polychondritis: Best Practice & Clinical Rheumatology. Best Pract Res Clin Rheumatol. mars 2023;37(1):101867.
  154. Fredeau L, Courvoisier DS, Ait Mehdi R, Ingen-Housz-Oro S, Mahe E, Costedoat-Chalumeau N, et al. Risk factors of progression from discoid lupus to severe systemic lupus erythematosus: a registry-based cohort study of 164 patients. J Am Acad Dermatol. mars 2023;88(3):551‑9.
  155. Felten R, Scherlinger M, Mertz P, Chasset F, Arnaud L. New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review. Joint Bone Spine. mars 2023;90(2):105523.
  156. Felten R, Meyer A, Gottenberg JE. Non-primary Sjogren’s Syndrome: Secondary or associated? Joint Bone Spine. mars 2023;90(2):105502.
  157. Felten R, Gottenberg JE. Response to: « Correspondence on “Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial” » by Wang et al. Ann Rheum Dis. mars 2023;82(3):e68.
  158. Agouti I, Masson E, Loundou A, Jean E, Arnaud L, Abdili E, et al. Plasma levels of E-selectin are associated with retinopathy in sickle cell disease. Eur J Haematol. mars 2023;110(3):271‑9.
  159. Ribault A, Benadjaoud MA, Squiban C, Arnaud L, Judicone C, Leroyer AS, et al. Circulating microvesicles correlate with radiation proctitis complication after radiotherapy. Sci Rep. 4 févr 2023;13(1):2033.
  160. Koga T, Umeda M, Yoshida N, Satyam A, Jha M, Scherlinger M, et al. Inhibition of calcium/calmodulin-dependent protein kinase IV in arthritis: dual effect on Th17 cell activation and osteoclastogenesis. Rheumatology (Oxford). 1 févr 2023;62(2):861‑71.
  161. Meyer A, Troyanov Y, Korathanakhun P, Landon-Cardinal O, Leclair V, Allard-Chamard H, et al. Myositis with prominent B cell aggregates may meet classification criteria for sporadic inclusion body myositis. Neuromuscul Disord. févr 2023;33(2):169‑82.
  162. Blaess J, Goepfert T, Geneton S, Irenee E, Gerard H, Taesch F, et al. Benefits & risks of physical activity in patients with Systemic Lupus Erythematosus: a systematic review of the literature. Semin Arthritis Rheum. févr 2023;58:152128.
  163. Cheminant M, Fox TA, Alligon M, Bouaziz O, Neven B, Moshous D, et al. Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity. Blood. 5 janv 2023;141(1):60‑71.
  164. Ishiguro N, Tanaka Y, Matsubara T, Atsumi T, Amano K, Sugiyama E, et al. Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years. Mod Rheumatol. 3 janv 2023;33(1):64‑72.
  165. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. janv 2023;82(1):3‑18.
  166. Israni M, Nicholson B, Mahlaoui N, Obici L, Rossi-Semerano L, Lachmann H, et al. Current Transition Practice for Primary Immunodeficiencies and Autoinflammatory Diseases in Europe: a RITA-ERN Survey. J Clin Immunol. janv 2023;43(1):206‑16.
  167. de Lamballerie X, Martin-Blondel G, Dupont A, Izopet J, Mentré F, Kamar N, et al. Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation. J Infect. janv 2023;86(1):66‑117.
  168. Beauvais C, Pereira B, Pham T, Sordet C, Claudepierre P, Fayet F, et al. Development and Validation of a Self-Administered Questionnaire Measuring Essential Knowledge in Patients With Axial Spondyloarthritis. J Rheumatol. janv 2023;50(1):56‑65.
  169. Renaudineau Y, Muller S, Hedrich CM, Chauveau D, Bellière J, De Almeida S, et al. Immunological and translational key challenges in systemic lupus erythematosus: A symposium update. J Transl Autoimmun. 2023;6:100199.
  170. Gérard É, Gemaye Kouadio T, Kalengayi Mbowa R, Martin T. [Not Available]. Sante Publique. 2023;34(HS2):261‑7.
  171. de Boysson H, Cuchet M, Cassius C, Cuchet P, Agard C, Audemard-Verger A, et al. Disease patterns and specific trajectories of anti-MDA5-related disease: a multicentre retrospective study of 70 adult patients. Front Immunol. 2023;14:1319957.
  172. Comarmond C, Drumez E, Labreuche J, Hachulla E, Thomas T, Flipo RM, et al. COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection. J Transl Autoimmun. 2023;6:100190.
  173. Cambon A, Rebelle C, Bachelier R, Arnaud L, Robert S, Lagarde M, et al. Macrophage IL-1β-positive microvesicles exhibit thrombo-inflammatory properties and are detectable in patients with active juvenile idiopathic arthritis. Front Immunol. 2023;14:1228122.
  174. Bekaddour N, Smith N, Beitz B, Llibre A, Dott T, Baudry A, et al. Targeting the chemokine receptor CXCR4 with histamine analog to reduce inflammation in juvenile arthritis. Front Immunol. 2023;14:1178172.
  175. Abellan Lopez M, Hutter L, Pagin E, Vélier M, Véran J, Giraudo L, et al. In vivo efficacy proof of concept of a large-size bioprinted dermo-epidermal substitute for permanent wound coverage. Front Bioeng Biotechnol. 2023;11:1217655.
  176. Solignac J, Lacroix R, Arnaud L, Abdili E, Bouchouareb D, Burtey S, et al. Rheopheresis Performed in Hemodialysis Patients Targets Endothelium and Has an Acute Anti-Inflammatory Effect. J Clin Med. 23 déc 2022;12(1).
  177. Guervilly C, Fournier T, Chommeloux J, Arnaud L, Pinglis C, Baumstarck K, et al. Ultra-lung-protective ventilation and biotrauma in severe ARDS patients on veno-venous extracorporeal membrane oxygenation: a randomized controlled study. Crit Care. 12 déc 2022;26(1):383.
  178. Beydoun N, Niberon Y, Arnaud L, Proust J, Nomenyo K, Zeng S, et al. Stabilization of Copper-Based Biochips with Alumina for Biosensing Application. Biosensors (Basel). 6 déc 2022;12(12).
  179. Alfatni A, Charles AL, Sauer F, Riou M, Goupilleau F, Talha S, et al. Peripheral Blood Mononuclear Cells Mitochondrial Respiration and Superoxide Anion after Heart Transplantation. J Clin Med. 6 déc 2022;11(23).
  180. Van Beckhoven D, Serrien B, Montourcy M, Verhofstede C, Van den Bossche D, Libois A, et al. Impact of COVID-19 on the Belgian HIV epidemic: slowdown of HIV transmission and testing and adaptation of care. BMC Infect Dis. 3 déc 2022;22(1):901.
  181. Scherlinger M, Pan W, Hisada R, Boulougoura A, Yoshida N, Vukelic M, et al. Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity. Sci Adv. 2 déc 2022;8(48):eadc9657.
  182. Trutschel D, Bost P, Mariette X, Bondet V, Llibre A, Posseme C, et al. Variability of Primary Sjögren’s Syndrome Is Driven by Interferon-α and Interferon-α Blood Levels Are Associated With the Class II HLA-DQ Locus. Arthritis Rheumatol. déc 2022;74(12):1991‑2002.
  183. Talarico R, Aguilera S, Alexander T, Amoura Z, Antunes AM, Arnaud L, et al. Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. Nat Rev Rheumatol. déc 2022;18(12):734.
  184. Sebbag E, Psimaras D, Baloglu S, Bourgmayer A, Moinard-Butot F, Barthélémy P, et al. Immune-Related Cerebellar Ataxia: A Rare Adverse Effect of Checkpoint Inhibitor Therapy. J Neuroimmune Pharmacol. déc 2022;17(3‑4):377‑9.
  185. Scherlinger M, Lemogne C, Felten R, Sibilia J. Excess of Post-Acute Sequelae of COVID-19 After the First Wave of the Pandemic. Infect Dis Ther. déc 2022;11(6):2279‑85.
  186. Murarasu A, Guettrot-Imbert G, Le Guern V, Yelnik C, Queyrel V, Schleinitz N, et al. Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study. Lancet Rheumatol. déc 2022;4(12):e842‑52.
  187. Laurent C, Lefèvre G, Kahn JE, Staumont-Salle D, Felten R, Puget M, et al. Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome. Br J Dermatol. déc 2022;187(6):1011‑3.
  188. Jeantin L, Lenfant T, Bataille P, de Boysson H, Cathébras P, Agard C, et al. Antineutrophil Cytoplasm Antibody-Associated Vasculitides Valvular Impairment: Multicenter Retrospective Study and Systematic Review of the Literature. J Rheumatol. déc 2022;49(12):1349‑55.
  189. Felten R, Lipsker D, Sibilia J, Chasset F, Arnaud L. The history of lupus throughout the ages. J Am Acad Dermatol. déc 2022;87(6):1361‑9.
  190. Ellezam B, Leclair V, Troyanov Y, Bersali I, Giannini M, Hoa S, et al. Capillary pathology with prominent basement membrane reduplication is the hallmark histopathological feature of scleromyositis. Neuropathol Appl Neurobiol. déc 2022;48(7):e12840.
  191. Bay P, de Chambrun MP, Rothstein V, Mahevas M, De Prost N, Roux A, et al. Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease. J Autoimmun. déc 2022;133:102941.
  192. Price E, Bombardieri M, Kivitz A, Matzkies F, Gurtovaya O, Pechonkina A, et al. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study. Rheumatology (Oxford). 28 nov 2022;61(12):4797‑808.
  193. Paccou J, Genser L, Lespessailles É, Bertin É, Javier RM, Duclos M, et al. French recommendations on the prevention and treatment of osteoporosis secondary to bariatric surgery. Joint Bone Spine. nov 2022;89(6):105443.
  194. Juge PA, Granger B, Debray MP, Ebstein E, Louis-Sidney F, Kedra J, et al. A Risk Score to Detect Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheumatol. nov 2022;74(11):1755‑65.
  195. Gottenberg JE, Chaudier A, Allenbach Y, Mekinian A, Amoura Z, Cacoub P, et al. Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases). RMD Open. nov 2022;8(2).
  196. El Khoury G, Hardy A, Saint-Etienne A, Saghbiny E, Meyer A, Grimaud O, et al. Return to Sport After Revision ACL Reconstruction: A Comparative Cohort Study of Outcomes After Single- Versus Multiple-Revision Surgeries. Orthop J Sports Med. nov 2022;10(11):23259671221133762.
  197. Boukhlal S, Felten R, Gervais E, Grardel B, Le Cam Y, Gottenberg JE, et al. Polymyalgia rheumatica associated with primary Sjögren’s syndrome: A French multicentric retrospective study. Joint Bone Spine. nov 2022;89(6):105447.
  198. Giannini M, Felten R, Gottenberg JE, Geny B, Meyer A. Inclusion body myositis and Sjögren’s syndrome: the association works both ways. Acta Neuropathol Commun. 24 oct 2022;10(1):152.
  199. Bruni C, Heidenreich S, Duenas A, Hoffmann-Vold AM, Gabrielli A, Allanore Y, et al. Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. Rheumatology (Oxford). 6 oct 2022;61(10):4035‑46.
  200. Rodère M, Pereira B, Soubrier M, Fayet F, Piperno M, Pallot-Prades B, et al. Development and validation of a self-administered questionnaire measuring essential knowledge in patients with rheumatoid arthritis. Rheumatol Int. oct 2022;42(10):1785‑95.
  201. Felten R, Geoffroy M, Bolko L, Duret PM, Desmurs M, Fan A, et al. Different anti-SARS-CoV-2 vaccine response under B- and T-cell targeted therapies versus anti-cytokine therapies in patients with inflammatory arthritides. Joint Bone Spine. oct 2022;89(5):105391.
  202. Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, Richez C, Truchetet ME, Wendling D, et al. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial. JAMA. 20 sept 2022;328(11):1053‑62.
  203. Mertz P, Piga M, Chessa E, Amoura Z, Voll RE, Schwarting A, et al. Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus. RMD Open. sept 2022;8(2).
  204. Fanesi A, Martin T, Breton C, Bernard O, Briandet R, Lopes F. The architecture and metabolic traits of monospecific photosynthetic biofilms studied in a custom flow-through system. Biotechnol Bioeng. sept 2022;119(9):2459‑70.
  205. Charlier P, Corde D, Bourdin V, Martin T, Tessier V, Donnelly M, et al. Toxicological analysis of a « poison vial » found in the remains of an SS soldier (Maltot, Normandy, France). Forensic Sci Med Pathol. sept 2022;18(3):244‑50.
  206. Simoncini S, Toupance S, Labat C, Gautier S, Dumoulin C, Arnaud L, et al. Functional Impairment of Endothelial Colony Forming Cells (ECFC) in Patients with Severe Atherosclerotic Cardiovascular Disease (ASCVD). Int J Mol Sci. 11 août 2022;23(16).
  207. Pan W, Scherlinger M, Yoshida N, Tsokos MG, Tsokos GC. PPP2R2D Suppresses Effector T Cell Exhaustion and Regulatory T Cell Expansion and Inhibits Tumor Growth in Melanoma. J Immunol. 1 août 2022;209(3):621‑8.
  208. Rose E, Ferrada MA, Quinn KA, Goodspeed W, Arnaud L, Sharma A, et al. Physician Global Assessment as a Disease Activity Measure for Relapsing Polychondritis. Arthritis Care Res (Hoboken). août 2022;74(8):1269‑76.
  209. Guffroy A, Dieudonné Y, Gies V, Danion F. Complex Allele with Additive Gain-of-Function STING1 Variants in a Patient with Cavitating Lung Lesions and Aspergillosis. J Clin Immunol. août 2022;42(6):1156‑9.
  210. Fayard D, Francès C, Amoura Z, Breillat P, Mathian A, Senet P, et al. Prevalence and factors associated with long-term remission in cutaneous lupus: A longitudinal cohort study of 141 cases. J Am Acad Dermatol. août 2022;87(2):323‑32.
  211. Richebé P, Coiffier G, Guggenbuhl P, Mulleman D, Couderc M, Dernis E, et al. Management and outcome of native joint septic arthritis: a nationwide survey in French rheumatology departments, 2016-2017. Ann Rheum Dis. 12 juill 2022;annrheumdis-2022-222143.
  212. Letarouilly JG, Pham T, Pierache A, Acquacalda É, Banneville B, Barbarot S, et al. New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study. Rheumatology (Oxford). 6 juill 2022;61(7):2848‑55.
  213. Seror R, Baron G, Camus M, Cornec D, Perrodeau E, Bowman SJ, et al. Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome. Ann Rheum Dis. juill 2022;81(7):979‑89.
  214. Hisada R, Yoshida N, Orite SYK, Umeda M, Burbano C, Scherlinger M, et al. Role of Glutaminase 2 in Promoting CD4+ T Cell Production of Interleukin-2 by Supporting Antioxidant Defense in Systemic Lupus Erythematosus. Arthritis Rheumatol. juill 2022;74(7):1204‑10.
  215. Barnig C, Lutzweiler G, Giannini M, Lejay A, Charles AL, Meyer A, et al. Resolution of Inflammation after Skeletal Muscle Ischemia-Reperfusion Injury: A Focus on the Lipid Mediators Lipoxins, Resolvins, Protectins and Maresins. Antioxidants (Basel). 20 juin 2022;11(6).
  216. Velier M, Mattei A, Simoncini S, Magalon J, Giraudo L, Arnaud L, et al. Paracrine Effects of Adipose-Derived Cellular Therapies in an in Vitro Fibrogenesis Model of Human Vocal Fold Scarring. J Voice. 13 juin 2022;S0892-1997(22)00145-X.
  217. Piga M, Chessa E, Morand EF, Ugarte-Gil MF, Tektonidou M, van Vollenhoven R, et al. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. Lancet Rheumatol. juin 2022;4(6):e441‑9.
  218. Hisada R, Yoshida N, Umeda M, Burbano C, Bhargava R, Scherlinger M, et al. The deacetylase SIRT2 contributes to autoimmune disease pathogenesis by modulating IL-17A and IL-2 transcription. Cell Mol Immunol. juin 2022;19(6):738‑50.
  219. Rose E, Ferrada MA, Quinn KA, Arnaud L, Goodspeed W, Kim J, et al. Discordance in patient and physician global assessment in relapsing polychondritis. Rheumatology (Oxford). 5 mai 2022;61(5):2025‑33.
  220. Daumas A, Magalon J, Jouve E, Casanova D, Philandrianos C, Abellan Lopez M, et al. Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis. Rheumatology (Oxford). 5 mai 2022;61(5):1936‑47.
  221. Widawski L, Fabacher T, Spielmann L, Gottenberg JE, Sibilia J, Duret PM, et al. Psoriatic arthritis with hyperuricemia: more peripheral, destructive, and challenging to treat. Clin Rheumatol. mai 2022;41(5):1421‑9.
  222. Tani C, Elefante E, Arnaud L, Barreira SC, Bulina I, Cavagna L, et al. Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation. Clin Exp Rheumatol. mai 2022;40 Suppl 134(5):93‑102.
  223. Talarico R, Aguilera S, Alexander T, Amoura Z, Andersen J, Arnaud L, et al. The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. Clin Exp Rheumatol. mai 2022;40 Suppl 134(5):3‑11.
  224. Schlencker A, Messer L, Ardizzone M, Blaison G, Hinschberger O, Dahan E, et al. Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study. Lupus Sci Med. mai 2022;9(1).
  225. Ruyssen-Witrand A, Boudali Y, Pane I, Cantagrel A, Thevenot P, Soubrier M, et al. Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry. Joint Bone Spine. mai 2022;89(3):105310.
  226. Petitdemange A, Sztejkowski C, Damian L, Martin T, Mouthon L, Amoura Z, et al. Treatment of relapsing polychondritis: a systematic review. Clin Exp Rheumatol. mai 2022;40 Suppl 134(5):81‑5.
  227. Mertz P, Arnaud L. Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a need for a more accurate control group? Ann Rheum Dis. mai 2022;81(5):e83.
  228. Lang E, Hardy A, Tufis O, Grimaud O, Gerometta A, Bohu Y, et al. Surgical technique of anterior cruciate ligament ligamentoplasty with pedicular hamstrings via an inside-out approach: BIOFAST hamstring tendons graft. Orthop Traumatol Surg Res. mai 2022;108(3):103192.
  229. Damian L, Pamfil C, Bucșa C, Nicula C, Mouthon L, Amoura Z, et al. Rare within rare. Necrotising scleritis and peripheral ulcerative keratitis: eye-threatening complications of relapsing polychondritis. Clin Exp Rheumatol. mai 2022;40 Suppl 134(5):86‑92.
  230. Chessa E, Piga M, Arnaud L. Physician global assessment in systemic lupus erythematosus: can we rely on its reliability? Ann Rheum Dis. mai 2022;81(5):e79.
  231. Bandeira M, Vieira A, Guimarães V, Bento T, Amoura Z, Arnaud L, et al. Off-label use of mycophenolate mofetil in the treatment of rare and complex rheumatic connective tissue diseases. Clin Exp Rheumatol. mai 2022;40 Suppl 134(5):32‑9.
  232. Baldini C, Arnaud L, Avčin T, Beretta L, Bellocchi C, Bouillot C, et al. Sjögren’s syndrome and other rare and complex connective tissue diseases: an intriguing liaison. Clin Exp Rheumatol. mai 2022;40 Suppl 134(5):103‑12.
  233. Abouyahya I, Liem SIE, Amoura Z, Fonseca JE, Chaigne B, Cutolo M, et al. Health-related quality of life in patients with mixed connective tissue disease: a comparison with matched systemic sclerosis patients. Clin Exp Rheumatol. mai 2022;40 Suppl 134(5):66‑70.
  234. Felten R, Giannini M, Gottenberg JE, Meyer A. Comment on: Refining myositis associated with primary Sjögren’s syndrome: data from the prospective cohort ASSESS: Reply. Rheumatology (Oxford). 11 avr 2022;61(4):e100.
  235. Pouchelon C, Visentini M, Emmi G, le Guern V, Quartuccio L, Samson M, et al. Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. Autoimmun Rev. avr 2022;21(4):103034.
  236. Hermine O, Mariette X, Porcher R, Djossou F, Nguyen Y, Arlet JB, et al. Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group. EClinicalMedicine. avr 2022;46:101362.
  237. Felten R, Rosine N. Responding to and Driving Change in Rheumatology: Report from the 12th International Immunology Summit 2021. Rheumatol Ther. avr 2022;9(2):705‑19.
  238. Rempenault C, Lukas C, Combe B, Herrero A, Pane I, Schaeverbeke T, et al. Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. Rheumatology (Oxford). 2 mars 2022;61(3):953‑62.
  239. Leclair V, D’Aoust J, Gyger G, Landon-Cardinal O, Meyer A, O’Ferrall E, et al. Autoantibody profiles delineate distinct subsets of scleromyositis. Rheumatology (Oxford). 2 mars 2022;61(3):1148‑57.
  240. Porta SV, Ugarte-Gil MF, García-de la Torre I, Bonfá E, Gómez-Puerta JA, Arnaud L, et al. Controversies in Systemic Lupus Erythematosus: Are We Treating Our Patients Adequately? J Clin Rheumatol. 1 mars 2022;28(2):e651‑8.
  241. Trefond L, Drumez E, Andre M, Costedoat-Chalumeau N, Seror R, Devaux M, et al. [Not Available]. Rev Rhum Ed Fr. mars 2022;89(2):192‑5.
  242. Spielmann L, Nespola B, Meyer A. Response to: « Immune-mediated necrotizing myopathies and interstitial lung disease are predominant characteristics in anti-Ku positive patients with idiopathic inflammatory myopathies » by Yang et al. Ann Rheum Dis. mars 2022;81(3):e49.
  243. El Kibbi L, Metawee M, Hmamouchi I, Abdulateef N, Halabi H, Eissa M, et al. Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries. Lancet Rheumatol. mars 2022;4(3):e160‑3.
  244. Boutin L, Caballero MJ, Guarrigue D, Hammad E, Rennuit I, Delhaye N, et al. Blunt Traumatic Aortic Injury Management, a French TraumaBase Analytic Cohort. Eur J Vasc Endovasc Surg. mars 2022;63(3):401‑9.
  245. Berthelot JM, Lioté F, Sibilia J. Tissue microbiota: A « secondary-self », first target of autoimmunity? Joint Bone Spine. mars 2022;89(2):105337.
  246. Beauvais C, Fayet F, Rousseau A, Sordet C, Pouplin S, Maugars Y, et al. Efficacy of a nurse-led patient education intervention in promoting safety skills of patients with inflammatory arthritis treated with biologics: a multicentre randomised clinical trial. RMD Open. mars 2022;8(1).
  247. Levy D, Giannini M, Oulehri W, Riou M, Marcot C, Pizzimenti M, et al. Long Term Follow-Up of Sarcopenia and Malnutrition after Hospitalization for COVID-19 in Conventional or Intensive Care Units. Nutrients. 21 févr 2022;14(4).
  248. Paul P, Picard C, Lyonnet L, Resseguier N, Hubert L, Arnaud L, et al. FCGR2A-HH Gene Variants Encoding the Fc Gamma Receptor for the C-Reactive Protein Are Associated with Enhanced Monocyte CD32 Expression and Cardiovascular Events’ Recurrence after Primary Acute Coronary Syndrome. Biomedicines. 19 févr 2022;10(2).
  249. Courties A, Deprouw C, Maheu E, Gibert E, Gottenberg JE, Champey J, et al. Effect of Transcutaneous Vagus Nerve Stimulation in Erosive Hand Osteoarthritis: Results from a Pilot Trial. J Clin Med. 18 févr 2022;11(4).
  250. Roy F, Korathanakhun P, Karamchandani J, Dubé BP, Landon-Cardinal O, Routhier N, et al. Myositis with prominent B-cell aggregates causing shrinking lung syndrome in systemic lupus erythematosus: a case report. BMC Rheumatol. 16 févr 2022;6(1):11.
  251. Scherlinger M, Zein N, Gottenberg JE, Rivière M, Kleinmann JF, Sibilia J, et al. Difficulties and Psychological Impact of the SARS-CoV-2 Pandemic in Patients with Systemic Lupus Erythematosus: A Nationwide Patient Association Study. Healthcare (Basel). 9 févr 2022;10(2).
  252. Mertz P, Lannes B, Nadaj Pakleza A, Meyer A, Guffroy A. Bilateral gastrocnemius myositis: an extra-intestinal manifestation of Crohn’s disease. Rheumatology (Oxford). 2 févr 2022;61(2):e35‑7.
  253. Levy D, Nespola B, Giannini M, Felten R, Severac F, Varoquier C, et al. Significance of Sjögren’s syndrome and anti-cN1A antibody in myositis patients. Rheumatology (Oxford). 2 févr 2022;61(2):756‑63.
  254. Iudici M, Jarlborg M, Lauper K, Müller-Ladner U, Smith V, Allanore Y, et al. Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database. Rheumatology (Oxford). 2 févr 2022;61(2):743‑55.
  255. Winthrop KL, Tanaka Y, Takeuchi T, Kivitz A, Matzkies F, Genovese MC, et al. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis. févr 2022;81(2):184‑92.
  256. Farge D, Loisel S, Resche-Rigon M, Lansiaux P, Colmegna I, Langlais D, et al. Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study. Lancet Rheumatol. févr 2022;4(2):e91‑104.
  257. Cavagna L, Meloni F, Meyer A, Sambataro G, Belliato M, De Langhe E, et al. Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies. Clin Exp Rheumatol. févr 2022;40(2):274‑83.
  258. Sauer F, Riou M, Charles AL, Meyer A, Andres E, Geny B, et al. Pathophysiology of Heart Failure: A Role for Peripheral Blood Mononuclear Cells Mitochondrial Dysfunction? J Clin Med. 29 janv 2022;11(3).
  259. Koumakis E, Cormier-Daire V, Dellal A, Debernardi M, Cortet B, Debiais F, et al. Osteogenesis Imperfecta: characterization of fractures during pregnancy and post-partum. Orphanet J Rare Dis. 28 janv 2022;17(1):22.
  260. Carapito R, Li R, Helms J, Carapito C, Gujja S, Rolli V, et al. Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. Sci Transl Med. 19 janv 2022;14(628):eabj7521.
  261. Takeuchi T, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, et al. Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). Mod Rheumatol. 5 janv 2022;32(1):59‑67.
  262. Trimaille A, Marchandot B, Oulehri W, Carmona A, Vollmer O, Poindron V, et al. Transient endothelial injury and release of lupus anticoagulant in COVID-19. J Thromb Thrombolysis. janv 2022;53(1):228‑30.
  263. Seror R, Camus M, Salmon JH, Roux C, Dernis E, Basch A, et al. Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry. Lancet Rheumatol. janv 2022;4(1):e8‑11.
  264. Felten R, Gallais F, Schleiss C, Chatelus E, Javier RM, Pijnenburg L, et al. Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab. Lancet Rheumatol. janv 2022;4(1):e13‑6.
  265. Felten R, Duret PM, Bauer E, Sedmak N, Djossou JH, Bensalem M, et al. B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics. Ann Rheum Dis. janv 2022;81(1):143‑5.
  266. Osswald D, Rameau AC, Terzic J, Sordet C, Bourcier T, Sauer A. Risk Factors Leading to Anti-TNF Alpha Therapies in Pediatric Severe Uveitis. Front Pediatr. 2022;10:802977.
  267. Giannini M, Ellezam B, Leclair V, Lefebvre F, Troyanov Y, Hudson M, et al. Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis. Front Immunol. 2022;13:974078.
  268. Gallais F, Gantner P, Planas D, Solis M, Bruel T, Pierre F, et al. Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine. Front Immunol. 2022;13:790212.
  269. Felten R, Lambert De Cursay G, Lespessailles E. Is there still a place for methotrexate in severe psoriatic arthritis? Ther Adv Musculoskelet Dis. 2022;14:1759720X221092376.
  270. Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis. 2022;14:1759720X211073001.
  271. Bandeira M, Di Cianni F, Marinello D, Arnaud L, Cannizzo S, Carta C, et al. An overlook on the current registries for rare and complex connective tissue diseases and the future scenario of TogethERN ReCONNET. Front Med (Lausanne). 2022;9:889997.
  272. Scherlinger M, Pijnenburg L, Chatelus E, Arnaud L, Gottenberg JE, Sibilia J, et al. Effect of SARS-CoV-2 Vaccination on Symptoms from Post-Acute Sequelae of COVID-19: Results from the Nationwide VAXILONG Study. Vaccines (Basel). 30 déc 2021;10(1).
  273. Cordel N, Derambure C, Coutant S, Mariette X, Jullien D, Debarbieux S, et al. TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1γ positive cancer-associated dermatomyositis. Rheumatology (Oxford). 1 déc 2021;60(12):5863‑7.
  274. Ugarte-Gil MF, Mak A, Leong J, Dharmadhikari B, Kow NY, Reátegui-Sokolova C, et al. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med. déc 2021;8(1).
  275. Truffot A, Gautier-Veyret E, Baillet A, Jourdil JF, Stanke-Labesque F, Gottenberg JE. Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis. Fundam Clin Pharmacol. déc 2021;35(6):1090‑9.
  276. Trefond L, Drumez E, Andre M, Costedoat-Chalumeau N, Seror R, Devaux M, et al. Impact of hydroxychloroquine used as DMARD on SARS-CoV-2 tests and infection evolution in a population of 871 patients with inflammatory rheumatic and musculoskeletal diseases. Joint Bone Spine. déc 2021;88(6):105226.
  277. Sezer HB, Hardy A, Bohu Y, Meyer A, Gerometta A, Grimaud O, et al. Treatment of Acute Bony Avulsion of Ischial Tuberosity With Cortical Screw Fixation. Arthrosc Tech. déc 2021;10(12):e2691‑8.
  278. Scherlinger M, Tsokos GC. Shortage of aspartate in mitochondria fuels arthritis. Nat Immunol. déc 2021;22(12):1474‑6.
  279. Richez C, Cordel N, Maillard H, Willems A, Chasset F, Belot A, et al. Practical management of patients on hydroxychloroquine. Joint Bone Spine. déc 2021;88(5 Suppl 1):105316.
  280. Retamozo S, Acar-Denizli N, Horváth IF, Ng WF, Rasmussen A, Dong X, et al. Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. Clin Exp Rheumatol. déc 2021;39 Suppl 133(6):166‑74.
  281. Rehberg M, Giegerich C, Praestgaard A, van Hoogstraten H, Iglesias-Rodriguez M, Curtis JR, et al. Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. Rheumatol Ther. déc 2021;8(4):1661‑75.
  282. Rehberg M, Giegerich C, Praestgaard A, van Hoogstraten H, Iglesias-Rodriguez M, Curtis JR, et al. Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. Rheumatol Ther. déc 2021;8(4):1921‑2.
  283. Guillot M, Charles AL, Lejay A, Pottecher J, Meyer A, Georg I, et al. Deleterious Effects of Remote Ischaemic Per-conditioning During Lower Limb Ischaemia-Reperfusion in Mice. Eur J Vasc Endovasc Surg. déc 2021;62(6):953‑9.
  284. Emad Y, Ragab Y, Robinson C, Pankl S, Young P, Fabi M, et al. Pulmonary vasculitis in Hughes-Stovin syndrome (HSS): a reference atlas and computed tomography pulmonary angiography guide-a report by the HSS International Study Group. Clin Rheumatol. déc 2021;40(12):4993‑5008.
  285. Dubost JJ, Couderc M, Pereira B, Mariette X, Seror R, Gottenberg JE, et al. Concomitant fibromyalgia in primary Sjögren’s syndrome in the French ASSESS cohort: comparison of the ACR 1990 and ACR 2016 criteria, FiRST questionnaire and physician’s opinion. Clin Exp Rheumatol. déc 2021;39 Suppl 133(6):140‑5.
  286. Combe B, Rincheval N, Berenbaum F, Boumier P, Cantagrel A, Dieude P, et al. Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. Rheumatology (Oxford). 3 nov 2021;60(11):5073‑9.
  287. Li J, Lei WT, Zhang P, Rapaport F, Seeleuthner Y, Lyu B, et al. Biochemically deleterious human NFKB1 variants underlie an autosomal dominant form of common variable immunodeficiency. J Exp Med. 1 nov 2021;218(11).
  288. van Vollenhoven RF, Bertsias G, Doria A, Isenberg D, Morand E, Petri MA, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. nov 2021;8(1).
  289. Giorgiutti S, Dieudonne Y, Hinschberger O, Nespola B, Campagne J, Rakotoarivelo HN, et al. Prevalence of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Spatial Association With Quarries in a Region of Northeastern France: A Capture-Recapture and Geospatial Analysis. Arthritis Rheumatol. nov 2021;73(11):2078‑85.
  290. Frede N, Rojas-Restrepo J, Caballero Garcia de Oteyza A, Buchta M, Hübscher K, Gámez-Díaz L, et al. Genetic Analysis of a Cohort of 275 Patients with Hyper-IgE Syndromes and/or Chronic Mucocutaneous Candidiasis. J Clin Immunol. nov 2021;41(8):1804‑38.
  291. Felten R, Dubois M, Ugarte-Gil MF, Chaudier A, Kawka L, Bergier H, et al. Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases. Rheumatology (Oxford). 9 oct 2021;60(SI):SI68‑76.
  292. Pelaccia T, Sibilia J, Fels É, Gauer L, Musanda A, Severac F, et al. And if we had to do it all over again, would we send medical students to the emergency departments during a pandemic? Lessons learned from the COVID-19 outbreak. Intern Emerg Med. oct 2021;16(7):1967‑74.
  293. Messer L, Felten R, Duret PM, Gottenberg JE, Widawski L, Meyer A, et al. [Which taxonomy for inflammatory diseases in rheumatology? The concept of Psout]. Med Sci (Paris). oct 2021;37(10):927‑32.
  294. Mariotte A, Bernardi L, Macquin C, DeCauwer A, Kotova I, Blüml S, et al. NKG2D ligands in inflammatory joint diseases: analysis in human samples and mouse models. Clin Exp Rheumatol. oct 2021;39(5):982‑7.
  295. Lévy D, Mariotte A, DeCauwer A, Macquin C, Pichot A, Molitor A, et al. Contrasting role of NLRP12 in autoinflammation: evidence from a case report and mouse models. RMD Open. oct 2021;7(3).
  296. Debien V, Petitdemange A, Bazin D, Ederle C, Nespola B, Merdji H, et al. New-onset systemic sclerosis and scleroderma renal crisis under docetaxel. J Scleroderma Relat Disord. oct 2021;6(3):306‑10.
  297. Chabot JM, Sibilia J. [Reforms of medical / health studies: in the middle of the ford]. Rev Prat. oct 2021;71(8):835‑40.
  298. Beauvais C, Gaud-Listrat V, Sellam J, Fayet F, Béranger M, Deparis N, et al. Patients’ safety skills assessment with biologics and JAK inhibitors: Update of the BioSecure questionnaire. Joint Bone Spine. oct 2021;88(5):105215.
  299. Kawka L, Schlencker A, Mertz P, Martin T, Arnaud L. Fatigue in Systemic Lupus Erythematosus: An Update on Its Impact, Determinants and Therapeutic Management. J Clin Med. 3 sept 2021;10(17).
  300. Spielmann L, Nespola B, Meyer A. Response to: « Overlap of systemic lupus erythematosus and myositis is rare in anti-Ku antibody-positive patients » by Ogawa-Momohara et al. Ann Rheum Dis. sept 2021;80(9):e148.
  301. Scherlinger M, Felten R, Gallais F, Nazon C, Chatelus E, Pijnenburg L, et al. Refining « Long-COVID » by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection. Infect Dis Ther. sept 2021;10(3):1747‑63.
  302. Kedra J, Seror R, Dieudé P, Constantin A, Toussirot E, Kfoury E, et al. Lymphoma complicating rheumatoid arthritis: results from a French case-control study. RMD Open. sept 2021;7(3).
  303. Felten R, Kawka L, Dubois M, Ugarte-Gil MF, Fuentes-Silva Y, Piga M, et al. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol. sept 2021;3(9):e613‑5.
  304. Collins A, Lendrem D, Wason J, Tarn J, Howard-Tripp N, Bodewes I, et al. Revisiting the JOQUER trial: stratification of primary Sjögren’s syndrome and the clinical and interferon response to hydroxychloroquine. Rheumatol Int. sept 2021;41(9):1593‑600.
  305. Rossi-Semerano L, Breton S, Semerano L, Boubaya M, Ohanyan H, Bossert M, et al. Application of the OMERACT synovitis ultrasound scoring system in juvenile idiopathic arthritis: a multicenter reliability exercise. Rheumatology (Oxford). 2 août 2021;60(8):3579‑87.
  306. Woudenberg T, Pelleau S, Anna F, Attia M, Donnadieu F, Gravet A, et al. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France. EBioMedicine. août 2021;70:103495.
  307. Willaume T, Felten R, Pijnenburg L, Lersy F, Bierry G. Spontaneous infarction of lumbar roots, vertebrae and paravertebral muscles. Am J Emerg Med. août 2021;46:796.e5-796.e7.
  308. Scherlinger M, Tsokos GC. Reactive oxygen species: The Yin and Yang in (auto-)immunity. Autoimmun Rev. août 2021;20(8):102869.
  309. Ellezam B, Leclair V, Troyanov Y, Meyer A, Hudson M, Landon-Cardinal O. Capillary basement membrane reduplication in myositis patients with mild clinical features of systemic sclerosis supports the concept of « scleromyositis ». Acta Neuropathol. août 2021;142(2):395‑7.
  310. Bergier H, Duron L, Sordet C, Kawka L, Schlencker A, Chasset F, et al. Digital health, big data and smart technologies for the care of patients with systemic autoimmune diseases: Where do we stand? Autoimmun Rev. août 2021;20(8):102864.
  311. Arends S, de Wolff L, van Nimwegen JF, Verstappen GMPJ, Vehof J, Bombardieri M, et al. Composite of Relevant Endpoints for Sjögren’s Syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatol. août 2021;3(8):e553‑62.
  312. Felten R, Scherlinger M, Guffroy A, Poindron V, Meyer A, Giannini M, et al. Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France. Arthritis Res Ther. 13 juill 2021;23(1):188.
  313. François P, Rusconi G, Arnaud L, Mariotta L, Giraudo L, Minonzio G, et al. Inter-center comparison of good manufacturing practices-compliant stromal vascular fraction and proposal for release acceptance criteria: a review of 364 productions. Stem Cell Res Ther. 1 juill 2021;12(1):373.
  314. Villon C, Orgeolet L, Roguedas AM, Misery L, Gottenberg JE, Cornec D, et al. Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS). Joint Bone Spine. juill 2021;88(4):105162.
  315. Spielmann L, Séverac F, Meyer A. Response to: « Anti-Ku syndrome with elevated CK: association with myocardial involvement in systemic sclerosis » by Campochiaro et al. Ann Rheum Dis. juill 2021;80(7):e114.
  316. Lefebvre F, Giannini M, Ellezam B, Leclair V, Troyanov Y, Hoa S, et al. Histopathological features of systemic sclerosis-associated myopathy: A scoping review. Autoimmun Rev. juill 2021;20(7):102851.
  317. Scherlinger M, Guillotin V, Douchet I, Vacher P, Boizard-Moracchini A, Guegan JP, et al. Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis. Sci Transl Med. 30 juin 2021;13(600):eabi4994.
  318. Arnaud L, Mertz P, Amoura Z, Voll RE, Schwarting A, Maurier F, et al. Patterns of fatigue and association with disease activity and clinical manifestations in systemic lupus erythematosus. Rheumatology (Oxford). 18 juin 2021;60(6):2672‑7.
  319. Wilhelm M, Bonam SR, Schall N, Bendorius M, Korganow AS, Lumbroso C, et al. Implication of a lysosomal antigen in the pathogenesis of lupus erythematosus. J Autoimmun. juin 2021;120:102633.
  320. Vollmer O, Tacquard C, Dieudonné Y, Nespola B, Sattler L, Grunebaum L, et al. Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent. Autoimmun Rev. juin 2021;20(6):102822.
  321. Toupin-April K, Décary S, de Wit M, Meara A, Barton JL, Fraenkel L, et al. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. Semin Arthritis Rheum. juin 2021;51(3):593‑600.
  322. Mertz P, Jeannel J, Guffroy A, Lescuyer S, Korganow AS, Rondeau-Lutz M, et al. Granulomatous manifestations associated with COVID19 infection: Is there a link between these two diseases? Autoimmun Rev. juin 2021;20(6):102824.
  323. Lukas C, Redondin M, Pane I, Soubrier M, Houvenagel E, Sibilia J, et al. Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE Registry. Clin Exp Rheumatol. juin 2021;39(3):501‑7.
  324. Sadras T, Martin M, Kume K, Robinson ME, Saravanakumar S, Lenz G, et al. Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. Mol Cell. 20 mai 2021;81(10):2094-2111.e9.
  325. Emad Y, Ragab Y, Kechida M, Guffroy A, Kindermann M, Robinson C, et al. A critical analysis of 57 cases of Hughes-Stovin syndrome (HSS). A report by the HSS International Study Group (HSSISG). Int J Cardiol. 15 mai 2021;331:221‑9.
  326. Fox RI, Fox CM, Gottenberg JE, Dörner T. Treatment of Sjögren’s syndrome: current therapy and future directions. Rheumatology (Oxford). 14 mai 2021;60(5):2066‑74.
  327. Schättin A, Häfliger S, Meyer A, Früh B, Böckler S, Hungerbühler Y, et al. Correction: Design and Evaluation of User-Centered Exergames for Patients With Multiple Sclerosis: Multilevel Usability and Feasibility Studies. JMIR Serious Games. 13 mai 2021;9(2):e30326.
  328. Schättin A, Häfliger S, Meyer A, Früh B, Böckler S, Hungerbühler Y, et al. Design and Evaluation of User-Centered Exergames for Patients With Multiple Sclerosis: Multilevel Usability and Feasibility Studies. JMIR Serious Games. 7 mai 2021;9(2):e22826.
  329. Dima A, Jurcut C, Arnaud L. Hydroxychloroquine in systemic and autoimmune diseases: Where are we now? Joint Bone Spine. mai 2021;88(3):105143.
  330. Dieudonné Y, Guffroy A, Poindron V, Sprauel PS, Martin T, Korganow AS, et al. B cells in primary antiphospholipid syndrome: Review and remaining challenges. Autoimmun Rev. mai 2021;20(5):102798.
  331. Demuth S, Felten R, Sordet C, Chatelus E, Chanson JB, Arnaud L. Rheumatic presentations of Guillain-Barré syndrome as a diagnostic challenge: A case series. Joint Bone Spine. mai 2021;88(3):105144.
  332. Chabot JM, Sibilia J. [A fool’s reform: the imbroglio of « intermediate professions »]. Rev Prat. mai 2021;71(5):482‑4.
  333. Retamozo S, Baldini C, Bootsma H, De Vita S, Dörner T, Fisher BA, et al. Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren’s Syndrome. Drugs Aging. avr 2021;38(4):265‑84.
  334. Felten R, Dubois M, Ugarte-Gil MF, Chaudier A, Kawka L, Bergier H, et al. Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases. Lancet Rheumatol. avr 2021;3(4):e243‑5.
  335. Cornet A, Andersen J, Myllys K, Edwards A, Arnaud L. Living with systemic lupus erythematosus in 2020: a European patient survey. Lupus Sci Med. avr 2021;8(1).
  336. Aitmehdi R, Arnaud L, Francès C, Senet P, Monfort JB, de Risi-Pugliese T, et al. Long-term efficacy and safety outcomes of lenalidomide for cutaneous lupus erythematosus: A multicenter retrospective observational study of 40 patients. J Am Acad Dermatol. avr 2021;84(4):1171‑4.
  337. Riou M, Oulehri W, Momas C, Rouyer O, Lebourg F, Meyer A, et al. Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 Infection. J Clin Med. 23 mars 2021;10(6).
  338. Hamidou M, Néel A, Poupon J, Amoura Z, Ebbo M, Sibilia J, et al. Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic). Arthritis Res Ther. 3 mars 2021;23(1):70.
  339. Juarez M, Diaz N, Johnston GI, Nayar S, Payne A, Helmer E, et al. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome. Rheumatology (Oxford). 2 mars 2021;60(3):1364‑75.
  340. Mertz P, Chalayer E, Amoura Z, Cathebras P, Chiche L, Coestedoat N, et al. Clinical spectrum and therapeutic management of auto-immune myelofibrosis: a nation-wide study of 30 cases. Haematologica. 1 mars 2021;106(3):871‑4.
  341. Talarico R, Aguilera S, Alexander T, Amoura Z, Antunes AM, Arnaud L, et al. The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. Nat Rev Rheumatol. mars 2021;17(3):177‑84.
  342. Pop R, Severac F, Happi Ngankou E, Harsan O, Martin I, Mihoc D, et al. Local anesthesia versus general anesthesia during endovascular therapy for acute stroke: a propensity score analysis. J Neurointerv Surg. mars 2021;13(3):207‑11.
  343. Pijnenburg L, Salem JE, Lebrun-Vignes B, Sibilia J, Javier RM, Arnaud L. Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study. Eur J Endocrinol. mars 2021;184(3):437‑44.
  344. Ferreira MB, Fonseca T, Costa R, Marinhoc A, Carvalho HC, Oliveira JC, et al. Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study. Eur J Intern Med. mars 2021;85:41‑9.
  345. Felten R, Devauchelle-Pensec V, Seror R, Duffau P, Saadoun D, Hachulla E, et al. Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis. mars 2021;80(3):329‑38.
  346. Boyer PH, Talagrand-Reboul É, Guffroy A, Schramm F, Jaulhac B, Grillon A. Direct examination of Gram-negative spiral-shaped rods: what is hidden behind the Campylobacter spp.? Clin Microbiol Infect. mars 2021;27(3):396‑7.
  347. Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, et al. Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial. Ann Rheum Dis. mars 2021;80(3):339‑48.
  348. Guervilly C, Bonifay A, Burtey S, Sabatier F, Cauchois R, Abdili E, et al. Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19. Blood Adv. 9 févr 2021;5(3):628‑34.
  349. Wienke J, Mertens JS, Garcia S, Lim J, Wijngaarde CA, Yeo JG, et al. Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk. Rheumatology (Oxford). 1 févr 2021;60(2):785‑801.
  350. Molto A, Gossec L, Poiraudeau S, Claudepierre P, Soubrier M, Fayet F, et al. Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA). Rheumatology (Oxford). 1 févr 2021;60(2):888‑95.
  351. Henes J, Oliveira MC, Labopin M, Badoglio M, Scherer HU, Del Papa N, et al. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica. 1 févr 2021;106(2):375‑83.
  352. Germain V, Scherlinger M, Barnetche T, Pichon C, Balageas A, Lequen L, et al. Role of stress in the development of rheumatoid arthritis: a case-control study. Rheumatology (Oxford). 1 févr 2021;60(2):629‑37.
  353. Felten R, Giannini M, Nespola B, Lannes B, Levy D, Seror R, et al. Refining myositis associated with primary Sjögren’s syndrome: data from the prospective cohort ASSESS. Rheumatology (Oxford). 1 févr 2021;60(2):675‑81.
  354. Courvoisier DS, Chatzidionysiou K, Mongin D, Lauper K, Mariette X, Morel J, et al. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology (Oxford). 1 févr 2021;60(2):820‑8.
  355. Scherlinger M, Lutz J, Galli G, Richez C, Gottenberg JE, Sibilia J, et al. Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatments. Semin Arthritis Rheum. févr 2021;51(1):36‑42.
  356. Jiang W, Levasseur W, Casalinho J, Martin T, Puel F, Perré P, et al. Shear stress computation in a millimeter thin flat panel photobioreactor: Numerical design validated by experiments. Biotechnol Appl Biochem. févr 2021;68(1):60‑70.
  357. Piga M, Arnaud L. The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand? J Clin Med. 11 janv 2021;10(2).
  358. Trouvin AP, Chenaf C, Riquelme M, Curis E, Nicolis I, Javier RM, et al. Opioid epidemic: Does rheumatological practice favors risk for patients? National survey on rheumatologists’ opioid prescriptions and compliance to guidelines for strong opioid prescription. Joint Bone Spine. janv 2021;88(1):105046.
  359. Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. janv 2021;80(1):36‑48.
  360. Kawka L, Mertz P, Chasset F, Lebrun-Vignes B, Salem JE, Arnaud L. Characterization of drug-induced cutaneous lupus: Analysis of 1994 cases using the WHO pharmacovigilance database. Autoimmun Rev. janv 2021;20(1):102705.
  361. Gallais F, Velay A, Nazon C, Wendling MJ, Partisani M, Sibilia J, et al. Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France. Emerg Infect Dis. janv 2021;27(1):113‑21.
  362. Aguiar F, Brito I, Sibilia J. Revisiting the association between systemic lupus erythematosus and gout. Reumatol Clin (Engl Ed). janv 2021;17(1):55‑6.
  363. Quéré B, Lemelle I, Lohse A, Pillet P, Molimard J, Richer O, et al. Juvenile Idiopathic Arthritis and COVID-19 Pandemic: Good Compliance With Treatment, Reluctance to Return to School. Front Med (Lausanne). 2021;8:743815.
  364. Petitdemange A, Felten R, Sibilia J, Martin T, Arnaud L. Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey. Ther Adv Musculoskelet Dis. 2021;13:1759720X211002595.
  365. Martinot M, Korganow AS, Wald M, Second J, Birckel E, Mahé A, et al. Case Report: A New Gain-of-Function Mutation of STAT1 Identified in a Patient With Chronic Mucocutaneous Candidiasis and Rosacea-Like Demodicosis: An Emerging Association. Front Immunol. 2021;12:760019.
  366. Lorenzo-Villalba N, Andrès E, Meyer A. Chronic Onset Form of Anti-HMG-CoA Reductase Myopathy. Eur J Case Rep Intern Med. 2021;8(7):002672.
  367. Gies V, Dieudonné Y, Morel F, Sougakoff W, Carapito R, Martin A, et al. Case Report: Acquired Disseminated BCG in the Context of a Delayed Immune Reconstitution After Hematological Malignancy. Front Immunol. 2021;12:696268.
  368. Aubergeon L, Sawaf M, Felten R, Gottenberg JE, Dumortier H, Monneaux F. High BTLA Expression Likely Contributes to Contraction of the Regulatory T Cell Subset in Lupus Disease. Front Immunol. 2021;12:767099.
  369. Alsaleh G, Panse I, Swadling L, Zhang H, Richter FC, Meyer A, et al. Autophagy in T cells from aged donors is maintained by spermidine and correlates with function and vaccine responses. Elife. 15 déc 2020;9.
  370. Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology (Oxford). 5 déc 2020;59(Suppl5):v29‑38.
  371. Solis M, Guffroy A, Lersy F, Soulier E, Gallais F, Renaud M, et al. Inadequate Immune Humoral Response against JC Virus in Progressive Multifocal Leukoencephalopathy Non-Survivors. Viruses. 2 déc 2020;12(12).
  372. Dieudonné Y, Meyer A. Author response: Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositis. Neurology. 1 déc 2020;95(22):1024.
  373. Chessa E, Piga M, Floris A, Devilliers H, Cauli A, Arnaud L. Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. Rheumatology (Oxford). 1 déc 2020;59(12):3622‑32.
  374. Monseau G, Landon-Cardinal O, Stenzel W, Schoindre Y, Mariampillai K, Barete S, et al. Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy. J Am Acad Dermatol. déc 2020;83(6):1759‑63.
  375. Meyer A, Spielmann L, Séverac F. Response to: « On using machine learning algorithms to define clinically meaningful patient subgroups » by Knevel and Huizinga. Ann Rheum Dis. déc 2020;79(12):e155.
  376. Meyer A, Spielmann L, Séverac F. Response to « Augmented vs. artificial intelligence for stratification of patients with myositis » by Mahler et al. Ann Rheum Dis. déc 2020;79(12):e163.
  377. Felten R, Arnaud L. Is it possible to stop glucocorticoids in systemic lupus? Joint Bone Spine. déc 2020;87(6):528‑30.
  378. Auloge P, Garnon J, Robinson JM, Dbouk S, Sibilia J, Braun M, et al. Interventional radiology and artificial intelligence in radiology: Is it time to enhance the vision of our medical students? Insights Imaging. 30 nov 2020;11(1):127.
  379. Guervilly C, Burtey S, Sabatier F, Cauchois R, Lano G, Abdili E, et al. Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19. J Infect Dis. 9 nov 2020;222(11):1789‑93.
  380. Zuily S, de Laat B, Guillemin F, Kelchtermans H, Magy-Bertrand N, Desmurs-Clavel H, et al. Anti-Domain I β2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study. J Appl Lab Med. 1 nov 2020;5(6):1242‑52.
  381. Vergne-Salle P, Pouplin S, Trouvin AP, Bera-Louville A, Soubrier M, Richez C, et al. The burden of pain in rheumatoid arthritis: Impact of disease activity and psychological factors. Eur J Pain. nov 2020;24(10):1979‑89.
  382. Rohmer J, Couteau-Chardon A, Trichereau J, Panel K, Gesquiere C, Ben Abdelali R, et al. Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients. Am J Hematol. nov 2020;95(11):1314‑23.
  383. Plüß M, Tampe B, Hakroush S, Niebusch N, Arnaud L, Korsten P. Therapeutic Implications of Renal Biopsies to Detect Proliferative Lupus Nephritis in Patients With Low-Grade Proteinuria. Kidney Int Rep. nov 2020;5(11):2120‑1.
  384. Mertz P, Schlencker A, Schneider M, Gavand PE, Martin T, Arnaud L. Towards a practical management of fatigue in systemic lupus erythematosus. Lupus Sci Med. nov 2020;7(1).
  385. Charles P, Dechartres A, Terrier B, Cohen P, Faguer S, Huart A, et al. Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. Rheumatology (Oxford). 1 oct 2020;59(10):2970‑5.
  386. Charles P, Dechartres A, Terrier B, Cohen P, Faguer S, Huart A, et al. Corrigendum to: Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. Rheumatology (Oxford). 1 oct 2020;59(10):3119.
  387. Pijnenburg L, Salem JE, Lebrun-Vignes B, Mallick A, Arnaud L, Javier RM. Answer to Tahri et al. « Retinoid Hyperostosis, an overlooked cause of atypical sacroiliac pain in young patients: A pharmacovigilance survey». Joint Bone Spine 2020. doi: 10.1016/j.jbspin.2020.06.023. Joint Bone Spine. oct 2020;87(5):523‑4.
  388. Meyer A, Spielmann L, Séverac F. On how to not misuse hierarchical clustering on principal components to define clinically meaningful patient subgroups. Response to: « On using machine learning algorithms to define clinical meaningful patient subgroups » by Pinal-Fernandez  and Mammen. Ann Rheum Dis. oct 2020;79(10):e129.
  389. Mertz P, Kleinmann JF, Lambert M, Puéchal X, Bonnin A, Boulon C, et al. Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective study. Autoimmun Rev. oct 2020;19(10):102634.
  390. Lobbes H, Dervout C, Toussirot E, Felten R, Sibilia J, Wendling D, et al. Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. Semin Arthritis Rheum. oct 2020;50(5):1109‑13.
  391. Giannini M, Grignaschi S, Fornaro M, Caporali R, Locatelli F, Zanframundo G, et al. Thrombocytopenia in idiopathic inflammatory myopathies: a case series analysis. Clin Exp Rheumatol. oct 2020;38(5):891‑5.
  392. Felten R, Chatelus E, Arnaud L. [Not Available]. Rev Rhum Ed Fr. oct 2020;87(5):322‑3.
  393. Bertolino J, Jouve E, Skopinski S, Agard C, Achille A, Thoreau B, et al. Characteristics of patients with systemic sclerosis suffering from a lower limb amputation: Results of a French collaborative study. J Scleroderma Relat Disord. oct 2020;5(3):224‑30.
  394. François P, Giraudo L, Veran J, Bertrand B, Dumoulin C, Aboudou H, et al. Development and Validation of a Fully GMP-Compliant Process for Manufacturing Stromal Vascular Fraction: A Cost-Effective Alternative to Automated Methods. Cells. 24 sept 2020;9(10).
  395. Mekinian A, Saadoun D, Vicaut E, Thietart S, Lioger B, Jego P, et al. Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial. Arthritis Res Ther. 17 sept 2020;22(1):218.
  396. Guffroy B, Ingwiller M, Gavand PE, Bouldoires B, Krummel T, Lioure B, et al. Flare of IGA glomerulonephritis under G-CSF stimulation regimen for autologous stem cell transplantation in systemic sclerosis. Rheumatology (Oxford). 1 sept 2020;59(9):e33‑4.
  397. Brito-Zerón P, Acar-Denizli N, Ng WF, Horváth IF, Rasmussen A, Seror R, et al. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren’s syndrome. Rheumatology (Oxford). 1 sept 2020;59(9):2350‑9.
  398. Trimaille A, Curtiaud A, Marchandot B, Matsushita K, Sato C, Leonard-Lorant I, et al. Venous thromboembolism in non-critically ill patients with COVID-19 infection. Thromb Res. sept 2020;193:166‑9.
  399. Nguyen MVC, Courtier A, Adrait A, Defendi F, Couté Y, Baillet A, et al. Fetuin-A and thyroxin binding globulin predict rituximab response in rheumatoid arthritis patients with insufficient response to anti-TNFα. Clin Rheumatol. sept 2020;39(9):2553‑62.
  400. Landon-Cardinal O, Baril-Dionne A, Hoa S, Meyer A, Leclair V, Bourré-Tessier J, et al. Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. RMD Open. sept 2020;6(2).
  401. Imperiale A, Poindron V, Martinez M, Ohlmann P, Schindler TH, El Ghannudi S. 68Ga-DOTATOC PET for Treatment Efficacy Evaluation of Cardiac Sarcoidosis. Clin Nucl Med. sept 2020;45(9):e416‑8.
  402. Guffroy A, Solis M, Gies V, Dieudonne Y, Kuhnert C, Lenormand C, et al. Progressive multifocal leukoencephalopathy and sarcoidosis under interleukin 7: The price of healing. Neurol Neuroimmunol Neuroinflamm. sept 2020;7(5).
  403. Giannini M, Ohana M, Nespola B, Zanframundo G, Geny B, Meyer A. Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? Eur Respir J. sept 2020;56(3).
  404. Felten R, Gottenberg JE. Advances in treatments for Sjögren’s syndrome: the glass is half full. Lancet Rheumatol. sept 2020;2(9):e516‑8.
  405. Duret PM, Sebbag E, Mallick A, Gravier S, Spielmann L, Messer L. Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. Ann Rheum Dis. sept 2020;79(9):1251‑2.
  406. Charles P, Perrodeau É, Samson M, Bonnotte B, Néel A, Agard C, et al. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial. Ann Intern Med. 4 août 2020;173(3):179‑87.
  407. Pizzimenti M, Meyer A, Charles AL, Giannini M, Chakfé N, Lejay A, et al. Sarcopenia and peripheral arterial disease: a systematic review. J Cachexia Sarcopenia Muscle. août 2020;11(4):866‑86.
  408. Molto A, Gossec L, Poiraudeau S, Claudepierre P, Soubrier M, Fayet F, et al. Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial. Semin Arthritis Rheum. août 2020;50(4):701‑8.
  409. Bohu Y, Klouche S, Sezer HB, Herman S, Grimaud O, Gerometta A, et al. Vancomycin-soaked autografts during ACL reconstruction reduce the risk of post-operative infection without affecting return to sport or knee function. Knee Surg Sports Traumatol Arthrosc. août 2020;28(8):2578‑85.
  410. Bohu Y, Klouche S, Sezer HB, Herman S, Grimaud O, Gerometta A, et al. Correction to: Vancomycin-soaked autografts during ACL reconstruction reduce the risk of post-operative infection without affecting return to sport or knee function. Knee Surg Sports Traumatol Arthrosc. août 2020;28(8):2586.
  411. Acar-Denizli N, Horváth IF, Mandl T, Priori R, Vissink A, Hernandez-Molina G, et al. Systemic phenotype related to primary Sjögren’s syndrome in 279 patients carrying isolated anti-La/SSB antibodies. Clin Exp Rheumatol. août 2020;38 Suppl 126(4):85‑94.
  412. Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. Neurology. 7 juill 2020;95(1):e70‑8.
  413. Meyer A, Guffroy A, Blaison G, Dieudonne Y, Amoura Z, Bonnotte B, et al. Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations. Lupus Sci Med. juill 2020;7(1).
  414. Felten R, Chatelus E, Arnaud L. How and why are rheumatologists relevant to COVID-19? Joint Bone Spine. juill 2020;87(4):279‑80.
  415. Injarabian L, Scherlinger M, Devin A, Ransac S, Lykkesfeldt J, Marteyn BS. Ascorbate maintains a low plasma oxygen level. Sci Rep. 30 juin 2020;10(1):10659.
  416. Corneloup M, Maurier F, Wahl D, Muller G, Aumaitre O, Seve P, et al. Disease-specific quality of life following a flare in systemic lupus erythematosus: an item response theory analysis of the French EQUAL cohort. Rheumatology (Oxford). 1 juin 2020;59(6):1398‑406.
  417. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. juin 2020;79(6):685‑99.
  418. Scherlinger M, Mertz P, Sagez F, Meyer A, Felten R, Chatelus E, et al. Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. Autoimmun Rev. juin 2020;19(6):102531.
  419. Morel J, Locci M, Banal F, Combe B, Cormier G, Dougados M, et al. Safety of surgery in patients with rheumatoid arthritis treated with tocilizumab: data from the French (REGistry -RoAcTEmra) Regate registry. Clin Exp Rheumatol. juin 2020;38(3):405‑10.
  420. Felten R, Duret PM, Gottenberg JE, Spielmann L, Messer L. At the crossroads of gout and psoriatic arthritis: « psout ». Clin Rheumatol. mai 2020;39(5):1405‑13.
  421. Dos Santos Rocha A, Scherlinger M, Ostermann L, Mehler DMA, Nadiradze A, Schulze F, et al. Characteristics and opinions of MD-PhD students and graduates from different European countries: a study from the European MD-PhD Association. Swiss Med Wkly. 6 avr 2020;150:w20205.
  422. Mattei A, Bertrand B, Jouve E, Blaise T, Philandrianos C, Grimaud F, et al. Feasibility of First Injection of Autologous Adipose Tissue-Derived Stromal Vascular Fraction in Human Scarred Vocal Folds: A Nonrandomized Controlled Trial. JAMA Otolaryngol Head Neck Surg. 1 avr 2020;146(4):355‑63.
  423. Scherlinger M, Schaeverbeke T. « To switch or not to switch »: the missing piece in the puzzle of biosimilar literature? Ann Rheum Dis. avr 2020;79(4):e36.
  424. Lugnier C, Meyer A, Talha S, Geny B. Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome? Pharmacol Ther. avr 2020;208:107475.
  425. Lefèvre G, Leurs A, Gibier JB, Copin MC, Staumont-Sallé D, Dezoteux F, et al. « Idiopathic Eosinophilic Vasculitis »: Another Side of Hypereosinophilic Syndrome? A Comprehensive Analysis of 117 Cases in Asthma-Free Patients. J Allergy Clin Immunol Pract. avr 2020;8(4):1329-1340.e3.
  426. Brilland B, Scherlinger M, Khoryati L, Goret J, Duffau P, Lazaro E, et al. Platelets and IgE: Shaping the Innate Immune Response in Systemic Lupus Erythematosus. Clin Rev Allergy Immunol. avr 2020;58(2):194‑212.
  427. Andrès E, Lorenzo Villalba N, Mourot-Cottet R, Maloisel F, Tebacher M, Gottenberg JE, et al. Severe Neutropenia and Agranulocytosis Related to Antithyroid Drugs: A Study of 30 Cases Managed in A Single Reference Center. Medicines (Basel). 19 mars 2020;7(3).
  428. Pottecher J, Noll E, Borel M, Audibert G, Gette S, Meyer C, et al. Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma  patients. Trials. 18 mars 2020;21(1):274.
  429. Dieudonné Y, Allenbach Y, Benveniste O, Leonard-Louis S, Hervier B, Mariampillai K, et al. Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositis. Neurology. 3 mars 2020;94(9):e910‑20.
  430. Vollmer O, Felten R, Mertz P, Lebrun-Vignes B, Salem JE, Arnaud L. Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: An analysis of 389 cases in VigiBase. Autoimmun Rev. mars 2020;19(3):102460.
  431. Chabot JM, Sibilia J. [Demography of health professions: history and perspective]. Rev Prat. mars 2020;70(3):259‑63.
  432. Duret PM, Meyer N, Saraux A, Devauchelle-Pensec V, Seror R, Le-Guern V, et al. Seasonal effect on fatigue, pain and dryness in primary Sjögren’s syndrome. Arthritis Res Ther. 24 févr 2020;22(1):39.
  433. Riou M, Pizzimenti M, Enache I, Charloux A, Canuet M, Andres E, et al. Skeletal and Respiratory Muscle Dysfunctions in Pulmonary Arterial Hypertension. J Clin Med. 3 févr 2020;9(2).
  434. Traineau H, Aggarwal R, Monfort JB, Senet P, Oddis CV, Chizzolini C, et al. Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. J Am Acad Dermatol. févr 2020;82(2):317‑25.
  435. Poindron V, Chatelus E, Canuet M, Gottenberg JE, Arnaud L, Gangi A, et al. T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients. Semin Arthritis Rheum. févr 2020;50(1):128‑34.
  436. Herber M, Mertz P, Dieudonné Y, Guffroy B, Jung S, Gies V, et al. Primary immunodeficiencies and lymphoma: a systematic review of literature. Leuk Lymphoma. févr 2020;61(2):274‑84.
  437. Felten R, Nespola B, Chatelus E, Arnaud L, Gottenberg JE, Canuet M, et al. Acute renal failure in systemic sclerosis revealing Goodpasture syndrome: « All that glitters is not scleroderma renal crisis ». J Scleroderma Relat Disord. févr 2020;5(1):NP1‑5.
  438. Alfatni A, Riou M, Charles AL, Meyer A, Barnig C, Andres E, et al. Peripheral Blood Mononuclear Cells and Platelets Mitochondrial Dysfunction, Oxidative Stress, and Circulating mtDNA in Cardiovascular Diseases. J Clin Med. 22 janv 2020;9(2).
  439. Meyer A, Troyanov Y, Drouin J, Oligny-Longpré G, Landon-Cardinal O, Hoa S, et al. Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Res Ther. 8 janv 2020;22(1):5.
  440. van Silfhout R, Pothin D, Martin T. White beam diagnostics using X-ray back-scattering from a CVD diamond vacuum window. J Synchrotron Radiat. 1 janv 2020;27(Pt 1):37‑43.
  441. Bodewes ILA, Gottenberg JE, van Helden-Meeuwsen CG, Mariette X, Versnel MA. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER randomized trial. Rheumatology (Oxford). 1 janv 2020;59(1):107‑11.
  442. Souberbielle JC, Cormier C, Cavalier E, Breuil V, Debiais F, Fardellone P, et al. Vitamin D Supplementation in France in patients with or at risk for osteoporosis: Recent data and new practices. Joint Bone Spine. janv 2020;87(1):25‑9.
  443. Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis. janv 2020;79(1):3‑18.
  444. Germain V, Scherlinger M, Barnetche T, Schaeverbeke T. Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect. Ann Rheum Dis. janv 2020;79(1):e11.
  445. Ruch Y, Kaeuffer C, Guffroy A, Lefebvre N, Hansmann Y, Danion F. Rapid Radiological Worsening and Cytokine Storm Syndrome in COVID-19 Pneumonia. Eur J Case Rep Intern Med. 2020;7(7):001822.
  446. Petitdemange A, Blaess J, Sibilia J, Felten R, Arnaud L. Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis. Ther Adv Musculoskelet Dis. 2020;12:1759720X20969261.
  447. Mariotte A, De Cauwer A, Po C, Abou-Faycal C, Pichot A, Paul N, et al. A mouse model of MSU-induced acute inflammation in vivo suggests imiquimod-dependent targeting of Il-1β as relevant therapy for gout patients. Theranostics. 2020;10(5):2158‑71.
  448. Lorenzo-Villalba N, Zulfiqar AA, Auburtin M, Schuhmacher MH, Meyer A, Maouche Y, et al. Thrombocytopenia in the Course of COVID-19 Infection. Eur J Case Rep Intern Med. 2020;7(6):001702.
  449. Jung S, Gies V, Korganow AS, Guffroy A. Primary Immunodeficiencies With Defects in Innate Immunity: Focus on Orofacial Manifestations. Front Immunol. 2020;11:1065.
  450. Gies V, Bekaddour N, Dieudonné Y, Guffroy A, Frenger Q, Gros F, et al. Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. Front Immunol. 2020;11:1409.
  451. Drouot L, Hantz S, Jouen F, Velay A, Lamia B, Veber B, et al. Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay. Front Microbiol. 2020;11:603931.
  452. Dieudonné Y, Uring-Lambert B, Jeljeli MM, Gies V, Alembik Y, Korganow AS, et al. Immune Defect in Adults With Down Syndrome: Insights Into a Complex Issue. Front Immunol. 2020;11:840.
  453. Bourse Chalvon N, Orquevaux P, Giusti D, Gatouillat G, Tabary T, Tonye Libyh M, et al. Absence of Anti-Glomerular Basement Membrane Antibodies in 200 Patients With Systemic Lupus Erythematosus With or Without Lupus Nephritis: Results of the GOODLUPUS Study. Front Immunol. 2020;11:597863.
  454. Boissier R, François P, Gondran Tellier B, Meunier M, Lyonnet L, Simoncini S, et al. Perirenal Adipose Tissue Displays an Age-Dependent Inflammatory Signature Associated With Early Graft Dysfunction of Marginal Kidney Transplants. Front Immunol. 2020;11:445.
  455. Blaess J, Walther J, Petitdemange A, Gottenberg JE, Sibilia J, Arnaud L, et al. Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage. Ther Adv Musculoskelet Dis. 2020;12:1759720X20959971.
  456. Berthelot JM, Lioté F, Maugars Y, Sibilia J. Lymphocyte Changes in Severe COVID-19: Delayed Over-Activation of STING? Front Immunol. 2020;11:607069.
  457. Antovic A, Svensson E, Lövström B, Illescas VB, Nordin A, Börjesson O, et al. Venous thromboembolism in anti-neutrophil cytoplasmic antibody-associated vasculitis: an underlying prothrombotic condition? Rheumatol Adv Pract. 2020;4(2):rkaa056.
  458. Pizzimenti M, Riou M, Charles AL, Talha S, Meyer A, Andres E, et al. The Rise of Mitochondria in Peripheral Arterial Disease Physiopathology: Experimental and Clinical Data. J Clin Med. 2 déc 2019;8(12).
  459. Matuszak J, Blondet C, Geny B, Namer IJ, Meyer A. Comment on: Muscle fluorodeoxyglucose uptake assessed by positron emission tomography-computed tomography as a biomarker of inflammatory myopathies disease activity: reply. Rheumatology (Oxford). 1 déc 2019;58(12):2345‑6.
  460. Meyer E, Labani A, Schaeffer M, Jeung MY, Ludes C, Meyer A, et al. Wide-volume versus helical acquisition in unenhanced chest CT: prospective intra-patient comparison of diagnostic accuracy and radiation dose in an ultra-low-dose setting. Eur Radiol. déc 2019;29(12):6858‑66.
  461. Klemm P, Assmann G, Preuss KD, Fadle N, Regitz E, Martin T, et al. Progranulin autoantibodies in systemic sclerosis and autoimmune connective tissue disorders: A preliminary study. Immun Inflamm Dis. déc 2019;7(4):271‑5.
  462. Cavagna L, Trallero-Araguás E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, et al. Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. J Clin Med. 18 nov 2019;8(11).
  463. Sibilia J. [Reform of medical studies: an unprecedented project]. Rev Prat. nov 2019;69(9):947‑51.
  464. Parisis D, Bernier C, Chasset F, Arnaud L. Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev. nov 2019;18(11):102393.
  465. Ben Hassine I, Rein C, Comarmond C, Glanowski C, Saidenberg-Kermanac’h N, Meunier B, et al. Osseous sarcoidosis: A multicenter retrospective case-control study of 48 patients. Joint Bone Spine. nov 2019;86(6):789‑93.
  466. Beauvais C, Rodère M, Pereira B, Legoupil N, Piperno M, Pallot Prades B, et al. Essential knowledge for patients with rheumatoid arthritis or spondyloarthritis: Results of a multicentric survey in France among health professionals and patients. Joint Bone Spine. nov 2019;86(6):747‑52.
  467. Lugnier C, Meyer A, Charloux A, Andrès E, Gény B, Talha S. The Endocrine Function of the Heart: Physiology and Involvements of Natriuretic Peptides and Cyclic Nucleotide Phosphodiesterases in Heart Failure. J Clin Med. 21 oct 2019;8(10).
  468. Ederlé C, Charles AL, Khayath N, Poirot A, Meyer A, Clere-Jehl R, et al. Mitochondrial Function in Peripheral Blood Mononuclear Cells (PBMC) Is Enhanced, Together with Increased Reactive Oxygen Species, in Severe Asthmatic Patients in Exacerbation. J Clin Med. 3 oct 2019;8(10).
  469. Lespessailles E, Paccou J, Javier RM, Thomas T, Cortet B. Obesity, Bariatric Surgery, and Fractures. J Clin Endocrinol Metab. 1 oct 2019;104(10):4756‑68.
  470. Tarn JR, Howard-Tripp N, Lendrem DW, Mariette X, Saraux A, Devauchelle-Pensec V, et al. Symptom-based stratification of patients with primary Sjögren’s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol. oct 2019;1(2):e85‑94.
  471. Richez C, Morel J, Sibilia J, Pham T. Practical management of patients on Janus kinase inhibitor (JAKi) therapy – the CRI fact sheets. Joint Bone Spine. oct 2019;86 Suppl 1:eS1.
  472. Richez C, Morel J, Cornec D, Daïen C, Goupille P, Lazaro E, et al. Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR). Joint Bone Spine. oct 2019;86 Suppl 1:eS2‑103.
  473. Pijnenburg L, Lipsker D, Mallick A, Proust F, Arnaud L, Javier RM. Cervical myelopathy revealing a unique case of retinoid hyperostosis. Joint Bone Spine. oct 2019;86(5):647‑9.
  474. Meyer A, Sibilia J. Strategy for suspected myositis. Joint Bone Spine. oct 2019;86(5):568‑75.
  475. Coignard-Biehler H, Mahlaoui N, Pilmis B, Barlogis V, Brosselin P, De Vergnes N, et al. A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency. J Clin Immunol. oct 2019;39(7):702‑12.
  476. Bouvard B, Confavreux CB, Briot K, Bonneterre J, Cormier C, Cortet B, et al. French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies. Joint Bone Spine. oct 2019;86(5):542‑53.
  477. Durel CA, Hot A, Trefond L, Aumaitre O, Pugnet G, Samson M, et al. Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. Rheumatology (Oxford). 1 sept 2019;58(9):1565‑73.
  478. Andrès E, Villalba NL, Zulfiqar AA, Serraj K, Mourot-Cottet R, Gottenberg AJE. State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies. J Clin Med. 1 sept 2019;8(9).
  479. Rinagel M, Chatelus E, Arnaud L, Jousse-Joulin S. [Contribution of Doppler ultrasound for the diagnosis of giant cell arteritis]. Presse Med. sept 2019;48(9):941‑7.
  480. Gorlier C, Gottenberg JE, Laurans L, Simon T, Ait-Oufella H, Sellam J. Serum level of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is a biomarker of synovitis in rheumatoid arthritis. Int J Rheum Dis. sept 2019;22(9):1616‑8.
  481. Bykerk VP, Östör AJK, Alvaro-Gracia J, Pavelka K, Román Ivorra JA, Nurmohamed MT, et al. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice. Clin Rheumatol. sept 2019;38(9):2411‑21.
  482. Gossec L, Fayet F, Soubrier M, Foissac F, Molto A, Richette P, et al. Is self-assessment by patients of disease activity acceptable over the long term in rheumatoid arthritis? A 3-year follow-up of 771 patients. Rheumatology (Oxford). 1 août 2019;58(8):1498‑9.
  483. Wienke J, Bellutti Enders F, Lim J, Mertens JS, van den Hoogen LL, Wijngaarde CA, et al. Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation. Arthritis Rheumatol. août 2019;71(8):1377‑90.
  484. Spielmann L, Nespola B, Séverac F, Andres E, Kessler R, Guffroy A, et al. Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes. Ann Rheum Dis. août 2019;78(8):1101‑6.
  485. Luxembourger C, Ruyssen-Witrand A, Ladhari C, Rittore C, Degboe Y, Maillefert JF, et al. A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients. Pharmacogenomics J. août 2019;19(4):368‑74.
  486. Dieudonné Y, Gies V, Guffroy A, Keime C, Bird AK, Liesveld J, et al. Transitional B cells in quiescent SLE: An early checkpoint imprinted by IFN. J Autoimmun. août 2019;102:150‑8.
  487. Aussy A, Fréret M, Gallay L, Bessis D, Vincent T, Jullien D, et al. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis. Arthritis Rheumatol. août 2019;71(8):1360‑70.
  488. Ronetti F, Acciai M, Ferraro D, Rech J, Jonckheere T, Martin T, et al. Symmetry Properties of Mixed and Heat Photo-Assisted Noise in the Quantum Hall Regime. Entropy (Basel). 25 juill 2019;21(8).
  489. Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, et al. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. JAMA. 23 juill 2019;322(4):315‑25.
  490. Anquetil C, Hachulla E, Machuron F, Mariette X, Le Guern V, Vittecoq O, et al. Is early-onset primary Sjögren’s syndrome a worse prognosis form of the disease? Rheumatology (Oxford). 1 juill 2019;58(7):1163‑7.
  491. Smith N, Rodero MP, Bekaddour N, Bondet V, Ruiz-Blanco YB, Harms M, et al. Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement-A new target for lupus treatment. Sci Adv. juill 2019;5(7):eaav9019.
  492. Scherlinger M, Carcaud C, Truchetet ME, Barnetche T, Duffau P, Couzi L, et al. Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study. Ann Rheum Dis. juill 2019;78(7):1007‑10.
  493. Messer L, Duret PM, Mallick A, Willaume T, Spielmann L, Chatelus E. Single tumor-like tophus. Joint Bone Spine. juill 2019;86(4):509‑10.
  494. Frantzen L, Cohen JD, Tropé S, Beck M, Munos A, Sittler MA, et al. Patients’ information and perspectives on biosimilars in rheumatology: A French nation-wide survey. Joint Bone Spine. juill 2019;86(4):491‑6.
  495. Felten R, Scher F, Sibilia J, Chasset F, Arnaud L. Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond. Joint Bone Spine. juill 2019;86(4):429‑36.
  496. Delaval L, Daumas A, Samson M, Ebbo M, De Boysson H, Liozon E, et al. Large-vessel vasculitis diagnosed between 50 and 60 years: Case-control study based on 183 cases and 183 controls aged over 60 years. Autoimmun Rev. juill 2019;18(7):714‑20.
  497. Arnaud L, Lebrun-Vignes B, Salem JE. Checkpoint inhibitor-associated immune arthritis. Ann Rheum Dis. juill 2019;78(7):e68.
  498. Rouyer O, Auger C, Charles AL, Talha S, Meyer A, Piquard F, et al. Effects of a High Fat Meal Associated with Water, Juice, or Champagne Consumption on Endothelial Function and Markers of Oxidative Stress and Inflammation in Young, Healthy Subjects. J Clin Med. 15 juin 2019;8(6).
  499. Paradis S, Charles AL, Georg I, Goupilleau F, Meyer A, Kindo M, et al. Aging Exacerbates Ischemia-Reperfusion-Induced Mitochondrial Respiration Impairment in Skeletal Muscle. Antioxidants (Basel). 8 juin 2019;8(6).
  500. Grimaud F, Yelnik C, Pineton de Chambrun M, Amoura Z, Arnaud L, Costedoat Chalumeau N, et al. Clinical and immunological features of antiphospholipid syndrome in the elderly: a retrospective national multicentre study. Rheumatology (Oxford). 1 juin 2019;58(6):1006‑10.
  501. Arnaud L, Gavand PE, Voll R, Schwarting A, Maurier F, Blaison G, et al. Predictors of fatigue and severe fatigue in a large international cohort of patients with systemic lupus erythematosus and a systematic review of the literature. Rheumatology (Oxford). 1 juin 2019;58(6):987‑96.
  502. Sebbag E, Felten R, Sagez F, Sibilia J, Devilliers H, Arnaud L. The world-wide burden of musculoskeletal diseases: a systematic analysis of the World Health Organization Burden of Diseases Database. Ann Rheum Dis. juin 2019;78(6):844‑8.
  503. Ramos-Casals M, Maria A, Suárez-Almazor ME, Lambotte O, Fisher BA, Hernández-Molina G, et al. Sicca/Sjögren’s syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). Clin Exp Rheumatol. juin 2019;37 Suppl 118(3):114‑22.
  504. Kostine M, Cappelli LC, Calabrese C, Calabrese LH, Bingham CO 3rd, Richez C, et al. Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists? Ann Rheum Dis. juin 2019;78(6):860‑2.
  505. Grillon A, Scherlinger M, Boyer PH, De Martino S, Perdriger A, Blasquez A, et al. Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. Semin Arthritis Rheum. juin 2019;48(6):1105‑12.
  506. Felten R, Scher F, Sibilia J, Gottenberg JE, Arnaud L. The pipeline of targeted therapies under clinical development for primary Sjögren’s syndrome: A systematic review of trials. Autoimmun Rev. juin 2019;18(6):576‑82.
  507. Leardini-Tristao M, Charles AL, Lejay A, Pizzimenti M, Meyer A, Estato V, et al. Beneficial Effect of Exercise on Cognitive Function during Peripheral Arterial Disease: Potential Involvement of Myokines and Microglial Anti-Inflammatory Phenotype Enhancement. J Clin Med. 10 mai 2019;8(5).
  508. Nguyen MVC, Adrait A, Baillet A, Trocmé C, Gottenberg JE, Gaudin P. Identification of cartilage oligomeric matrix protein as biomarker predicting abatacept response in rheumatoid arthritis patients with insufficient response to a first anti-TNFα treatment. Joint Bone Spine. mai 2019;86(3):401‑3.
  509. Mertz P, Belot A, Cervera R, Chuah TY, Dagna L, Damian L, et al. The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. Joint Bone Spine. mai 2019;86(3):363‑8.
  510. Guillaume-Jugnot P, Badoglio M, Labopin M, Terriou L, Yakoub-Agha I, Martin T, et al. Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Clin Rheumatol. mai 2019;38(5):1501‑11.
  511. Dieudonné Y, Guffroy A, Vollmer O, Carapito R, Korganow AS. IKZF1 Loss-of-Function Variant Causes Autoimmunity and Severe Familial Antiphospholipid Syndrome. J Clin Immunol. mai 2019;39(4):353‑7.
  512. Berthelot JM, Sibilia J. Trained Immunity and Autoimmune Disease: Did Eve Sin before Adam? Joint Bone Spine. mai 2019;86(3):293‑5.
  513. Scherlinger M, Schaeverbeke T. Response to: « Switching from the bio-originators to biosimilar: is it premature to recommend this procedure? » by Cantini and Benucci. Ann Rheum Dis. avr 2019;78(4):e24.
  514. Scherlinger M, Schaeverbeke T. Additional response to the correspondence: « Switching from the bio-originators to biosimilar: is it premature to recommend this procedure? » by Cantini and Bennuci. Ann Rheum Dis. avr 2019;78(4):e26.
  515. Scherlinger M, Langlois E, Germain V, Schaeverbeke T. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). Semin Arthritis Rheum. avr 2019;48(5):927‑32.
  516. Arnaud L, Mertz P, Gavand PE, Martin T, Chasset F, Tebacher-Alt M, et al. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Ann Rheum Dis. avr 2019;78(4):504‑8.
  517. Matuszak J, Blondet C, Hubelé F, Gottenberg JE, Sibilia J, Bund C, et al. Muscle fluorodeoxyglucose uptake assessed by positron emission tomography-computed tomography as a biomarker of inflammatory myopathies disease activity. Rheumatology (Oxford). 8 mars 2019;kez040.
  518. Magalon J, Velier M, Simoncini S, François P, Bertrand B, Daumas A, et al. Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis. Ann Rheum Dis. mars 2019;78(3):391‑8.
  519. Chasset F, Richez C, Martin T, Belot A, Korganow AS, Arnaud L. Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers). Joint Bone Spine. mars 2019;86(2):165‑71.
  520. Mouasni S, Gonzalez V, Schmitt A, Bennana E, Guillonneau F, Mistou S, et al. The classical NLRP3 inflammasome controls FADD unconventional secretion through microvesicle shedding. Cell Death Dis. 25 févr 2019;10(3):190.
  521. Sibilia J. [Periodic certification of physicians for personalized professional development]. Rev Prat. févr 2019;69(2):135‑6.
  522. Daste C, Rannou F, Mouthon L, Sanchez K, Roren A, Tiffreau V, et al. Patient acceptable symptom state and minimal clinically important difference for patient-reported outcomes in systemic sclerosis: A secondary analysis of a randomized controlled trial comparing personalized physical therapy to usual  care. Semin Arthritis Rheum. févr 2019;48(4):694‑700.
  523. Bouis D, Kirstetter P, Arbogast F, Lamon D, Delgado V, Jung S, et al. Severe combined immunodeficiency in stimulator of interferon genes (STING) V154M/wild-type mice. J Allergy Clin Immunol. févr 2019;143(2):712-725.e5.
  524. Schleiss C, Ilias W, Tahar O, Güler Y, Miguet L, Mayeur-Rousse C, et al. BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo. Sci Rep. 24 janv 2019;9(1):701.
  525. Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, et al. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ. 24 janv 2019;364:l67.
  526. Guffroy A, Dieudonné Y, Uring-Lambert B, Goetz J, Alembik Y, Korganow AS. Infection risk among adults with down syndrome: a two group series of 101 patients in a tertiary center. Orphanet J Rare Dis. 11 janv 2019;14(1):15.
  527. Rinagel M, Chatelus E, Jousse-Joulin S, Sibilia J, Gottenberg JE, Chasset F, et al. Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: a systematic review and meta-analysis of the literature. Autoimmun Rev. janv 2019;18(1):56‑61.
  528. Mertz P, Lebrun-Vignes B, Salem JE, Arnaud L. Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase. J Allergy Clin Immunol. janv 2019;143(1):433‑6.
  529. Hadjadj J, Guffroy A, Delavaud C, Taieb G, Meyts I, Fresard A, et al. Progressive Multifocal Leukoencephalopathy in Primary Immunodeficiencies. J Clin Immunol. janv 2019;39(1):55‑64.
  530. Briot K, Paccou J, Beuzeboc P, Bonneterre J, Bouvard B, Confavreux CB, et al. French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation. Joint Bone Spine. janv 2019;86(1):21‑8.
  531. Yuan M, Custaud MA, Xu Z, Wang J, Yuan M, Tafforin C, et al. Multi-System Adaptation to Confinement During the 180-Day Controlled Ecological Life Support System (CELSS) Experiment. Front Physiol. 2019;10:575.
  532. Virone A, Bastard JP, Fellahi S, Capeau J, Rouanet S, Sibilia J, et al. Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis. RMD Open. 2019;5(2):e000897.
  533. Sanosyan A, Daien C, Nutz A, Bollore K, Bedin AS, Morel J, et al. Discrepancy of Serological and Molecular Patterns of Circulating Epstein-Barr Virus Reactivation in Primary Sjögren’s Syndrome. Front Immunol. 2019;10:1153.
  534. Pottecher J, Meyer A, Wenceslau CF, Timmermans K, Hauser CJ, Land WG. Editorial: Trauma-Induced, DAMP-Mediated Remote Organ Injury, and Immunosuppression in the Acutely Ill Patient. Front Immunol. 2019;10:1971.
  535. Martin M, Martinez C, Arnaud L, Weber JC, Poindron V, Blaison G, et al. Association of antiphospholipid antibodies with active digital ulceration in systemic sclerosis. RMD Open. 2019;5(2):e001012.
  536. Gossec L, Soubrier M, Foissac F, Molto A, Richette P, Beauvais C, et al. Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients. RMD Open. 2019;5(2):e000914.
  537. Felten R, Scher F, Sagez F, Chasset F, Arnaud L. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2019;13:1535‑43.
  538. Felten R, Sagez F, Gavand PE, Martin T, Korganow AS, Sordet C, et al. 10 most important contemporary challenges in the management of SLE. Lupus Sci Med. 2019;6(1):e000303.
  539. Felten R, Perrin P, Caillard S, Moulin B, Javier RM. Avascular osteonecrosis in kidney transplant recipients: Risk factors in a recent cohort study and evaluation of the role of secondary hyperparathyroidism. PLoS One. 2019;14(2):e0212931.
  540. Felten J, Cogne K, Fischbach-Boulanger C, Falcoz PE, Meyer A, Olland A, et al. Atypical Right Pulmonary Artery Dissection Complicating Severe Blunt Chest Trauma. Semin Thorac Cardiovasc Surg. Spring 2019;31(1):137‑9.
  541. Brito-Zerón P, Retamozo S, Kostov B, Baldini C, Bootsma H, De Vita S, et al. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome. RMD Open. 2019;5(2):e001064.
  542. Meyer A, Scirè CA, Talarico R, Alexander T, Amoura Z, Avcin T, et al. Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines [corrected]. RMD Open. 2018;4(Suppl 1):e000784.